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ABSTRACT
Engineering Cell-Free Protein Synthesis Technology for Codon Reassignment,
Biotherapeutics Production Using Just-Add-Water System, and
Biosensing Endocrine Disrupting Compounds
Sayed Mohammad Amin Salehi
Department of Chemical Engineering, BYU
Doctor of Philosophy
Cell-free protein synthesis is an emerging technology that has many applications. The
open nature of this system makes it a compelling technology that can be manipulated to answer
many needs that are unavailable in other systems. This dissertation reports on engineering this
technology for: 1) sense codon emancipation for incorporation of multiple unnatural amino acids;
2) expressing a hard-to-express anticancer biotherapeutic and introducing a just-add-water
system; 3) a biosensing ligand that interacts with nuclear hormone receptors.
Emancipating sense codons toward a minimized genetic code is of significant interest to
science and engineering. A promising approach to sense codon emancipation is the targeted in
vitro removal of native tRNA. Here we introduce a new in-vitro or “cell-free” approach to
emancipate sense codons via efficient and affordable degradation of endogenous tRNA using
RNase-coated superparamagnetic beads. The presented method removes greater than 99% of
tRNA in cell lysates, while preserving cell-free protein synthesis activity. The resulting tRNAdepleted lysate is compatible with in vitro-transcribed synthetic tRNA for the production of
peptides and proteins.
Biotherapeutics have many promising applications, such as anti-cancer treatments,
immune suppression, and vaccines. However, due to their biological nature, some
biotherapeutics can be challenging to rapidly express and screen for activity through traditional
recombinant methods. In this work, we demonstrate the use of cell-free systems for the
expression and direct screening of the difficult-to-express cytotoxic protein onconase. Using cellfree systems, onconase can be rapidly expressed in soluble, active form. Furthermore, the open
nature of the reaction environment allows for direct and immediate downstream characterization
without the need of purification. Also, we report the ability of a “just-add-water” lyophilized
cell-fee system to produce onconase.
Here we introduce a Rapid Adaptable Portable In-vitro Detection biosensor platform
(RAPID) for detecting ligands that interact with nuclear hormone receptors (NHRs). The
biosensor is based on an engineered, allosterically-activated fusion protein, which contains the
ligand binding domain from a target NHR. The presented RAPID biosensor platform is
significantly faster and less labor intensive than commonly available technologies, making it a
promising tool for detecting environmental EDC contamination and screening potential NHRtargeted pharmaceuticals.
Keywords: Sayed Mohammad Amin Salehi, cell-free protein synthesis, codon emancipation,
cancer biotherapeutics, endocrine disrupting compounds, nuclear hormone receptors, biosensor
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INTRODUCTION

Overview
Cell-free synthetic biology is an emerging technology that promises to change our lives
in ways in the near future. For decades, using living cells to produce useful and varied products
from biofuels to cancer drugs has been an essential part of our life [1]; however, in vivo synthesis
of products has some limitations. In order to survive, each cell must spend energy and use its
machinery to maintain its viability, thus limiting the energy and machinery that can be used to
produce the desired product. Moreover, in many cases the cell’s membrane inhibits the mass
transfer of necessary raw materials into the cell or products out of the cell. In addition, some
desired products are toxic to the cell and contaminations or viral infections continually threaten
cell fermentations. Cell-free synthetic biology is a unique approach that can address these and
many other limitations involved in using living cells.
Cell-free synthetic biology is the activation of complex biological processes outside of
cells, so there is no cell that needs to be kept alive and energy/machinery can be focused on
producing the desired products. This technology was first used to discover the genetic code
around 50 years ago. However, only recently have researchers had the knowledge and tools
necessary to truly take advantage of the cell-free platform to economically produce complex
commercial products [2, 3]. Cell-free synthetic biology has opened new opportunities for new
synthesized products. This technology enables direct access to and manipulation of the complex
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reactions that usually take place inside of living cells [3, 4]. In this way, all reactions can be
controlled and optimized to identify bottlenecks and improve product yield [2]. Furthermore,
purification of products is simpler from a cell-free environment. These benefits of cell-free
synthetic biology make it a powerful tool to produce compounds that are difficult to produce in
cells.

Scope of the Projects
In this work, we aimed to expand applications of the cell-free technology by engineering
this system for: 1) expanding the genetic code by emancipating sense codons, 2) producing hard
to express cancer biotherapeutics and introducing the Just-add-water system, and 3) biosensing
ligands that interact with nuclear hormone receptors.

1.2.1

Expanding the Genetic Code
Life uses a canon of 20 primary amino acids and 64 codons as its code. This is conserved

across living organisms and is known as the genetic code - with the exception of some rare
species that have slight changes in their genetic code as a response to changes in their
environment and energy sources [5]. From the 64 available codons, three codons act as stop
codons, TAG (amber), TAA (ochre), and TGA (opal); consequently, the 61 remaining codons
are considered as sense codons, and they code for the 20 amino acids. Therefore, some codons
code for the same amino acid, and there is promiscuity among them. The idea behind expanding
the genetic codes is to reprogram some of the codons to incorporate unnatural amino acids
(uNAA). This idea could produce an almost infinite number of new proteins.
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The early studies tried to site-specifically incorporate unnatural amino acids into protein
by using chemically aminoacylated suppressor tRNA in response to an amber stop codon [6, 7].
Bain et. al. [8] in another study developed a method to incorporate unnatural amino acids by
creating a 65th codon-anticodon pair from unnatural nucleoside bases having non-standard
hydrogen-bonding patterns. These remarkable efforts were followed by the Schultz lab discovery.
Instead of using chemical methods, they introduced orthogonal a tyrosyl tRNA/Synthetase pair
from methanocaldococcus jannaschii to E. coli to incorporate unnatural amino acid in response
to the amber stop codon [9, 10]. This tRNA must not be recognized by native E. coli aminoacyltRNA synthetases and act efficiently to deliver novel amino acids into the translation process.
This work introduced a new method to expand the genetic code and add unnatural amino acids.
Following this discovery, researchers could successfully expand the genetic code for
Saccharomyces cerevisiae as a eukaryote [11], and mammalian cells [12]. In addition to this
method, Anderson et. al. [13] used orthogonal tRNA/aminoacyl-tRNA synthetase pair in
response to the quadruplet codon, AGGA, in E. coli. These methods made a platform for
expanding the genetic code both in vivo [12] and in vitro [14].
However, the current technologies for incorporating uNAA into protein suffer from some
limitations that have narrowed the applications of uNAA incorporation. These limitations include:
1) inefficient/inaccurate uNAA incorporation due to competition with endogenous (native)
components with exogenous (foreign) components (which causes the approximately 30%
efficiency commonly observed with current technology), 2) exponential amplification of
inefficiencies for incorporation of multiple unnatural amino acids (e.g. less than 1% of product
would be correct if 4 uNAA are incorporated), and 3) difficulty in incorporating different types
of unnatural amino acids simultaneously [12, 15, 16].
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This study seeks to address these issues and enable efficient simultaneous incorporation
of multiple different unnatural amino acids by using a novel CFPS approach.

1.2.2

Cancer Biotherapeutics Production Using CFPS
From 1991 to 2012 the cancer death rate dropped by 23 percent constituting nearly 1.7

million lives saved [17]. Much of this success could be attributed to the advances in targeted
therapies such as monoclonal antibody therapeutics [18, 19] and anticancer peptides [20, 21].
Still, cancer remains the second leading cause of death in the United States and is projected to
overtake heart disease in the next few years [22] with a projected 1,685,210 new cancer cases
and 595,690 deaths in 2016 [17].
The development of targeted oncological therapies in the field of protein biologics has
revolutionized our ability to treat cancer. To date, all FDA-approved anticancer protein biologics
have been produced in vivo [19] where 69% of those have been produced recombinantly in E.
coli [19]. As successful as in vivo production has been and continues to be, there are still many
drawbacks to the closed, transport-limited in vivo environment including 1) inability to produce
cytotoxic proteins at high yields, 2) transport inhibition of non-natural components, 3) a walledin environment that complicates direct in situ monitoring, control, and dynamic optimization of
required reagents (e.g cofactors, redox, translation elements), and 4) a crowded environment that
can inhibit the correct folding of complex proteins [2, 4, 23]. The open, non-living environment
provided by cell-free technology overcomes these limitations allowing the production of
cytotoxic proteins [24, 25], unnatural amino acid (uAA) incorporation [23, 26], and the rapid
synthesis of personalized medicines [27].
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The open nature and facile manipulation of the cell-free environment allows for greater
control, monitoring, and high-throughput screening techniques for improved protein evolution
compared to the in vivo method [3, 23, 28, 29]. While standard E. coli-based cell-free systems
lack the ability to perform glycosylation, the potential of using hybrid cell-free lysates and the
addition of exogenous components has the promise of overcoming this limitation [30, 31]. All of
these aspects combined with the high toxicity tolerance of CFPS makes this system a compelling
platform for rapidly developing, screening, and producing difficult to express anticancer
biotherapeutic proteins.
One emerging application in cancer research where cell-free technology is vital is the
synthesis of personalized vaccines to more quickly and efficiently treat certain types of cancers.
Previous work reported that vaccine proteins for anti-cancer therapeutics could be produced
rapidly in E. coli-based cell-free systems [32]. In that study, complex fusion of Granulocyte
macrophage colony-stimulating factor (GM-CSF) and B-lymphocyte Id scFv with different
arrangements were produced successfully with CFPS [27]. Importantly cell-free reagents can be
stockpiled and then scaled for reliable consistent production at the microliter, milliliter, or liter
scale. Thus the major limitation becomes the time required for synthesizing the DNA that
templates of CFPS and custom DNA can now be economically synthesized in as little as a day.
While the implementation of customized immune therapy soon after diagnosis on a large scale
requires further research and streamlining; simple, rapid and economical production of
personalized anti-cancer therapeutics may soon be practicable using cell-free technology [27].
While many proteins of oncological value are produced recombinantly in vivo [19], cellfree technologies could contribute to improving the effectiveness and economics of these and
future therapeutics. For example, the cell-free technologies of protein evolution with ribosome
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display can improve the solubility and activity of protein therapeutics [3, 28, 33]. Another
important technology in oncological therapies is that of anticancer peptides. Anticancer peptides
in many cases have higher target specificity, lower intrinsic toxicity, and greater ease of
modification compared to full-length proteins used in chemotherapy [21, 34, 35]. Peptides can
also be fused to cell penetrating moieties to better target and treat cancer [34]. Some of these
modification schemes include attaching radionuclides, hormones, vaccines, or other drugs to a
nascent peptide [36]. One great challenge in the development of clinically viable therapeutic
anticancer peptides is improving delivery, minimizing non-specific toxic effects, and a greater
understanding of pharmacokinetic properties [20].
While peptides are traditionally produced by chemical synthesis or in vivo via nucleotide
sequences, these methods have significant drawbacks in time scale and cost [37]. Cell-free
technologies offer a compelling platform that could be explored to rapidly and more efficiently
study, screen, and produce similar peptides on an industrial level [4, 23, 37]. For example, Lee et.
al. developed a strategy for rapid cell-free expression and recovery of multiple peptide molecules
[37]. They optimized peptide production by developing a DNA construct with an enhanced
sequence for improved translation efficiency, protease resistance, purification recovery, and
cleavage efficiency. Continued engineering of cell-free technologies such as these demonstrates
how cell-free systems could be utilized for the automated, rapid production of clinically viable
pure proteins and peptides that have significant oncological value.
Taking advantage of these benefits, we engineered CFPS to produce a hard to express
anticancer protein biotherapeutics, onconase. We expanded our lyophilized CFPS and introduced
the just-add-water system. The presented method showed huge advantages over in vivo
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production of onconase by reducing the expression and screening time of onconase from several
weeks to a few hours.

1.2.3

Biosensing Endocrine Disrupting Compounds
Nuclear hormone receptors (NHRs) are involved in vital functions of the cells including:

metabolism, homeostasis, differentiation, development, and reproduction [38, 39]. NHRs interact
with many natural and synthetic ligands and about 4% of all currently marketed therapeutics
interfere with the activity of one or more NHR [40]. Understanding effects and interactions
between these therapeutics and NHRs is critical to developing new drugs and improving
available ones. For instance, many NHRs have multiple subtypes and isoforms with a high
degree of homology but different functionalities [41]. Many diseases are the result of one of
these subtype’s or isoform’s disorder, but many drugs have agonist or antagonist activity against
the whole family or multiple subtypes of a NHR, which can cause significant side effects. The
demand for subtype-selective therapeutics, in addition to difficulties in their development require
screening of them, which in turn brings about the necessity of a fast, inexpensive, and robust
screening method against NHRs [41, 42].
NHRs can also be targeted by endocrine disrupting chemicals (EDCs), which have
become a public safety concern due to their ability to interfere with naturally occurring endocrine
control. EDCs have been found in common dietary, environmental, and household chemicals and
have been linked to diverse diseases and disorders, including multiple cancers, developmental
disorders, and other epigenetic dysfunction [43, 44]. Due to the risk EDCs pose to the endocrine
systems in humans and other animals, in 1996 the Environmental Protection Agency (EPA)
listed approximately 10,000 chemicals of concern and established a two-tier screening system in
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which the first tier is simply the assay of a compound’s endocrine disrupting activity. According
to the EPA, as of May 2014, only 109 chemicals (~1% of EPA list) have been actively screened
as potential EDCs [45]. Despite the ability of currently available assays to generate substantial
data on suspected endocrine disruptors, they remain low throughput, expensive, and require
lengthy laboratory analysis. These complications thus limit current EDC assays to a laboratory
setting with extensive capital and consumable costs. Due to the sheer enormity in number, most
chemicals and mixtures in commerce worldwide, therefore, remain largely uncharacterized for
endocrine disrupting activity. Many of the EDCs implicated in these trends affect the endocrine
system in human and animals, and commonly have an affinity for specific NHRs. This important
class of EDCs interacts with human and animal NHRs through their ligand-binding domains by
mimicking natural hormones [46]. Examples of these include medical and industrial
xenoestrogens, such as diethylstilbestrol (DES) and bisphenol-A (BPA), as well as naturally
occurring phytoestrogens, such and genistein and daidzein [47-49].
For these reasons, numerous in vivo and in vitro ECD assays have been developed, each
with their advantages and disadvantages [45, 50-52]. Mammalian cell and live animal assays are
generally the most reliable for the detection and prediction of the biological effects of a test
chemical [53]. However, animal and most mammalian cell assays are expensive, time-consuming
and labor-intensive, making them unrealistic for high-throughput screening. In addition, live
animal data can be profoundly affected by very subtle confounders, including feed nutrient and
phytoestrogen levels, maternal stress, intrauterine position, seasonal changes, dosing levels and
timing, cage materials, housing strategies, strains used, differences in measurement techniques,
and selection of endpoints, among others [54-57]. A final limitation of animal assays is that they
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cannot indicate the specific target and mechanism of a particular endocrine-active chemical,
particularly if gross morphology or metabolic effects are observed as endpoints.
Specific determinations of target and activity, however, can be made by direct ligandbinding assays in vitro, which are fast and have the potential to screen large libraries in a highthroughput manner [58, 59]. These assays typically evaluate the binding of test ligands to a
purified ligand binding domain, or whole receptor, by quantifying the displacement of a labeled
ligand standard [60]. The primary drawback to these methods is that they require the receptor
ligand binding domains to be expressed and/or purified in a stable and active form, and remain
stable during the testing procedure. These assays also require isolation and labeling of the
relevant NHR proteins and/or ligands.
Engineered yeast-based transcriptional assays are another type of assay which provide a
good compromise between the simplicity of direct binding assays and the complexity of native
cellar assays [61]. Yeast systems based on engineered intracellular ligand-binding-domainreporter-protein fusions are also simple and relatively inexpensive. However, they are still timeconsuming, and a significant drawback to the yeast system is the apparent ability of yeast to
actively export many classes of small molecules. It has been suggested that the efflux of
chemicals is a mechanism of general drug resistance, and has led to problems in detecting and
classifying some known endocrine disruptor chemicals by yeast-based methods [62].
Considering the available assays, there remains a need for a robust, inexpensive, rapid,
high-throughput-capable assay, which can both detect various chemicals that target NHRs in
diverse environments and be easily adopted for the broad range of human and animal NHRs. In
this work, we introduce a new class of biosensor for detecting ligand that interact with nuclear
hormone receptors. This CFPS-based biosensor is significantly faster and less labor intensive
9

than commonly available technologies, making it a promising tool for detecting environmental
EDC contamination and screening potential NHR-targeted pharmaceuticals.

Outline
The bulk of this dissertation is based on publications where I was the primary author and
led this work. However, I also received significant help from colleagues and collaborators.
Colleagues and collaborators who assisted in the work described are listed at the start of each
chapter.
Chapter 2: Codon Emancipation with A Cell-Free Platform: Highly Efficient tRNA
Degradation Coupled with Custom tRNA Synthesis
This chapter is an adaptation of the article entitled “Efficient tRNA Degradation and
Quantification in Escherichia Coli Cell Extract Using RNase-Coated Magnetic Beads: A Key
Step Towards Codon Emancipation” submitted for publication in March 2017 to Biotechnology
Progress.
Chapter 3: Onconase Production and a Just-Add-Water Cell-Free System
This chapter is an adaptation of an article entitled “Cell-free protein synthesis of a
cytotoxic cancer therapeutics: Onconase production and a just-add-water cell-free system”
published on September 2015 in Biotechnology Journal, and “Escherichia coli-based cell-free
extract development for protein-based cancer therapeutic production” published on April 2016 in
International Journal of Development Biology.
Chapter 4: A Cell-free Protein Synthesis Approach to Biosensing hTRβ-Specific
Endocrine Disruptors
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This chapter is an adaptation of a research paper entitled “Cell-Free Protein Synthesis
Approach to Biosensing hTRβ-Specific Endocrine Disruptors” published on February 2017 in
Analytical Chemistry, ACS Publication.
Chapter 5: Conclusion and Future Work
In this chapter, I propose some directions to expand these projects as part of future work.
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2

CODON EMANCIPATION WITH A CELL-FREE PLATFORM: HIGHLY
EFFICIENT tRNA DEGRADATION COUPLED WITH CUSTOM TRNA
SYNTHESIS

This chapter is adaptation of a paper entitled “Efficient tRNA Degradation and
Quantification in Escherichia Coli Cell Extract Using RNase-Coated Magnetic Beads: A Key
Step Towards Codon Emancipation” submitted for publication in March. This work was
developed and led by myself with the help of Mark T. Smith, Song-Min Schinn, Jeremy M. Hunt,
Christina Muhlestein, Joann Diray-Arc, Dr. Brent Nielsen, and Dr. Bradley Bundy.
Emancipating sense codons toward a minimized genetic code is of significant interest to
science and engineering. A promising approach to sense codon emancipation is the targeted in
vitro removal of native tRNA. However, challenges remain such as the insufficient depletion of
tRNA in lysate-based in vitro systems and the high cost of the purified components system
(PURE). Here we introduce a new in vitro or “cell-free” approach to emancipate sense codons
via efficient and affordable degradation of endogenous tRNA using RNase-coated
superparamagnetic beads. The presented method removes greater than 99% of tRNA in cell
lysates, while preserving cell-free protein synthesis activity. The resulting tRNA-depleted lysate
is compatible with in vitro-transcribed synthetic tRNA for the production of peptides and
proteins.
Introduction
A minimized genetic code promises to expand the available proteomic toolset with
implications in many fields, including biotherapeutics [63, 64], biocatalysis [65], protein labeling
[66], and minimal cells [67]. Such a rewriting of the genetic code requires the decoupling and
reengineering of the codon-tRNA-amino acid relationships, which define the genetic coding of
proteins by nucleic acids [68]. These relationships, while extremely functional and adaptive, are
also redundant, promiscuous and complex [69, 70]. In theory, the great redundancy of codontRNA-amino acid relations has the potential to be exploited for incorporation of unnatural amino
12

acids. Indeed, promising efforts have expanded the genetic code using stop codons or 4-base
codons [9, 71]. Unfortunately, these methods are constrained by a limited number of available
codons for emancipation, or by competition from native tRNA and release factors. The
emancipation of sense codons has the potential to free up high numbers of codons for efficient
unnatural amino acid incorporation. However, sense codon reassignment has been met with
many challenges such as low fidelity or poor rates of incorporation [72-75]. Furthermore, the
extensive reassignment of sense codons throughout the genome would necessitate massive
mutagenesis or complete genome replacement to maintain the production of active endogenous
proteins and maintain cell viability. Here we present an efficient and cost-effective alternative
strategy where the codon-tRNA-amino acid relationship is reengineered in an open and highly
customizable in vitro environment.
In vitro or “cell-free” protein synthesis systems provide a compelling platform to
decouple the codon-tRNA-amino acid relationship for multiple reasons: 1) The system utilizes
harvested biological machinery (e.g. ribosomes, elongation factors, tRNA synthetases), thus
genome-wide mutagenesis replacing sense codons is not necessary to maintain the activity of
transcription/translation enzymes. 2) The system is “dead”, allowing for manipulations that
would devastate in vivo systems such as the complete removal or degradation of tRNA. 3) The
system is open, facilitating direct addition of heterologous machinery and exquisite control of
reaction conditions such as pH, osmolarity, and reagent concentration [23, 76]. Based on these
features, the genomic code could be minimized and manipulated by complete or near-complete
destruction of the native tRNA followed by repopulation with a synthetic minimal set of tRNA
(Figure 2-1).
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Figure 2-1 Schematic of the in vitro codon emancipation approach demonstrated in this work.
The cell extract is treated using RNase A-coated magnetic beads to efficiently degrade
endogenous tRNA. Synthetic tRNA, produced using in vitro transcription, is used to repopulate
the cell-free system with only the desired tRNA, resulting in codon emancipation.

A recent study illustrated the potential of a cell-free protein synthesis system as a
platform to reengineer the codon-tRNA-amino acid relationship by demonstrating the decoding
of 61 sense codons by synthetic tRNAs at various efficiencies [77, 78]. The complete
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emancipation of sense codons, however, was limited due to insufficient removal of native tRNA
by chromatography, at an average of 62% of a specific tRNA removed [77, 78]. The PURE
system, where individually purified transcription/translation components are combined, also has
the potential to emancipate codons, but the monetary high cost severely limits its utility [77, 78].
Here we report a new approach for near-complete depletion of native tRNA from E. coli cell
extracts as a cost-effective platform to emancipate sense codons in vitro. Such efficient tRNA
depletion is essential to reduce the competition between the native and synthetic coding elements
for high fidelity codon reassignment. The presented method is compatible with various
approaches of synthetic tRNA production, including in vitro transcription of T7-promoted tRNA,
T7-promoted hammerhead Ribozyme-tRNA, and flexizyme [77, 79, 80]. Additionally, for the
first time we directly measured residual tRNA using quantitative real-time PCR and report the
inaccuracy of assuming tRNA removal based solely on the indirect method of protein expression
levels.

Material and Methods

2.2.1

Cell Extract Preparation and Treatment to Deplete Endogenous tRNA
Cell extract preparation was performed as previously described [81] using E. coli BL21

Star™ (DE3) strain. To treat the cell extract and remove endogenous tRNA, RNase A from
bovine pancreas (Sigma) was covalently attached to epoxy superparamagnetic beads
(Dynabeads® M-270 Epoxy, Invitrogen) according to the manufacturer protocol. Briefly, the
reaction buffer containing 0.02M monosodium phosphate, 0.08M disodium phosphate, 3M
ammonium sulfate, and 6mg/ml RNase A was prepared. 60 mg of epoxy beads were resuspended
in 2ml of dimethylformamide (DMF) to a final bead concentration of 4x109 beads per mL. Beads
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were washed two times with PBS/Tween 20 (0.5%Vol) buffer and one time with PBS buffer.
Each time beads were separated from the buffer by magnetic force using DynaMag™- Spin
Magnet (Life Technology). After washing the beads, an equivalent volume of reaction buffer
was added to the beads which were then incubated at 37oC for 24h with end-over-end shaking.
After the reaction, beads were washed extensively with PBS/Tween and PBS, in order to remove
all unattached RNase A, and were stored in PBS buffer. For cell extract treatment, the extract
was first incubated at room temperature with 0.5mM phenylmethylsulfonyl fluoride (PMSF) for
5 min to decrease protease activity of the extract before adding RNase A beads. After PMSA
treatment, the cell extract was treated with RNase A on beads at a final concentration of 17.5
beads per ml extract and incubated at room temperature with end-over-end shaking. Treated
extract was separated by DynaMag™- Spin Magnet and transferred to a new microcentrifuge
tube (Figure 2-2) and stored at -80oC.

2.2.2

Total RNA Purification and qPCR
To investigate the tRNA cleavage efficiency, tRNA was first purified from RNase A

treated extract and non-treated extract using Trizol reagent (ThermoFisher Scientific) and
isopropanol in the form of total RNA. Briefly, 1 equivalent volume of Trizol reagent and 0.2
equivalent volumes of chloroform were added to the cell extracts followed by centrifugation at
15000 RCF for 15 min. The top layers containing the RNA were transferred to new
microcentrifuge tubes and RNA was precipitated using 1.45 equivalent volumes of isopropanol
and 0.45 equivalent volumes of 8 M ammonium acetate. The mixtures were incubated at -20oC
for 20 min and centrifuged at 15000 RCF for 15 min. The pellets were washed with 75% ethanol
and centrifuged for 5 min at 15000 RCF. RNA pellets were resupended in RNAse free water.
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For qPCR, reverse complementary DNAs were polymerized using ThermoScript™
Reverse Transcriptase (ThermoFisher Scientific) and reverse primers (Table 2-1) according to
the manufacturer protocol. The products of this step were subjected to real time quantitative
PCR using KAPA SYBR® FAST qPCR Kits (Kapa Biosystems).
Table 2-1 List of primers used for qPCR of various tRNAs to measure residual tRNA level in
treated cell extracts compared to untreated cell extract
Residue

Anti-Codon Codon
(5` to 3`) (5` to 3`)

Reverse primer (5' to 3')

Forward Primer (5' to 3')

Ala

GGC

GCC

GCT GAC CTC TTG CAT GCC AT

GGG GCT ATA GCT CAG CTG G

Arg

CCG

CGG

CCT GAG ACC TCT GCC TCC GGA

GCG CCC GTA GCT CAG CTG GAT A

Glu

UCC

GAA

CCC CTG TTA CCG CCG TGA AAG G

GTC CCC TTC GTC TAG AGG CCC AG

Ser

CGA

UCG

GTA GAG TTG CCC CTA CTC CGG T

GGA GAG ATG CCG GAG CGG

Val

UAC

GUA

CGC CGA CCC CCT CCT TGT AAG

GGG TGA TTA GCT CAG CTG GGA GAG C

2.2.3

In vitro Transcription of tRNA
To produce synthetic tRNA, forward and reverse complementary Ultramer® DNA
oligonucleotides (Integrated DNA Technology, forward sequences reported in

Figure 2-5,c) were combined and amplified using a PCR technique. In vitro transcription of
tRNA was performed at 37oC for 2 hr with shaking at 150 RPM using the following reaction
conditions: 50mM Tris-Cl pH 7.5, 30 mM MgCl2, 5 mM DTT, 5.5 mM spermidine, 2 mM
putrescine, 2 mM NTPs, 2 mg/ml Poly(vinylsulfonic acid, sodium salt) (PVSA), 0.1 mg/ml T7
RNA polymerase, and 10 ug/ml DNA template.

2.2.4

Cell-free Protein Synthesis (CFPS)
Cell-free protein synthesis (CFPS) was performed in a PANOxSP system as described in

previous studies [82], with the crucial modification of not adding E. coli tRNA mixture. The
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reaction contained 33.33mM phosphoenolpyruvate (PEP; Roche Molecular Biochemicals),
10mM magnesium glutamate, 10mM ammonium glutamate, 175mM potassium glutamate,
2.7mM potassium oxalate, 1mM diaminobutane, 1.5mM spermidine, 0.33mM nicotinamide
adenine dinucleotide (NAD), 0.27mM coenzyme A (CoA), 1.2mM ATP, 0.86mM CTP, 0.86mM
GTP, 0.86mM UTP, 0.17mM folinic Acid, 2mM concentrations of 19 canonical amino acids
(excluding glutamate), and 12 nM DNA. All components were obtained from Sigma Aldrich (St.
Louis, MO), unless explicitly stated otherwise.
pY71sfGFP vector [15], prepared using Qiagen Maxi-Prep kits, templated the sfGFP cellfree reactions. The sfGFP yield was determined by fluorescence with a Synergy MX microplate
reader (BioTek Instruments, Winooski, VT, USA). The DNA 1 construct shown in Figure 2-6,a
was synthesized by GenScript and cloned into vector pET-9a under a T7 promoter. 5 µM
radiolabled-14C valine (PerkinElmer Inc., Waltham, MA) was added to the CFPS reaction and
the protein yield was measured using scintillation counting based on total and washed sample, as
previously described [83].

Results and Discussion
To emancipate sense codons and reassign them, the following two steps were performed:
1) native tRNA depletion, where codon-tRNA-amino acid relationships are decoupled, and 2)
repopulation of the system with a synthetic set of tRNA, where codon-tRNA-amino acid
relationships are reorganized according to a minimal genetic code (Figure 2-1). In this work, we
present a method of near-complete tRNA depletion in cell extracts and directly measured the
residual native tRNA. The treated extract was capable of producing various proteins and peptides
using purified native tRNA or synthetic tRNA.
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2.3.1

tRNA Depletion of Cell Extract
Inspired by a previous study where tRNA was degraded with RNase A, RNase A was

assessed for its ability to degrade tRNA from our system (Figure 2-2) [84]. To optimize RNase
exposure for both tRNA depletion and preservation of translation-essential rRNAs, RNase A
molecules were covalently immobilized to epoxy-functionalized superparamagnetic beads.
RNase A-coated beads enable: 1) control of RNase A concentration by adjusting bead
concentrations, 2) control of treatment time, 3) rapid removal of RNase A by magnetic force, and
4) facile homogenous mixing of RNAse A to achieve uniform treatment of cell extracts. Bead
concentration, treatment time, washing and cleaning steps were fine-tuned to maximize tRNA
degradation and rRNA preservation, as discussed below.
RNase A-bead treatment for 15 min with 17.5 µl RNase A-beads per ml cell extract
(3.5x107 beads/ml) was sufficient to inhibit protein synthesis (Figure 2-3,a, 1st and 2nd bars).
However, after the RNase-coated beads were removed from the cell-extract and 2 mg/ml bulkpurified tRNA was supplied, less than 10% of its original protein synthesis capability was
retained (Figure 2-3,a, 4th bar). The possibility of residual RNase A in the system, which would
degrade translation-essential mRNA, was assessed by adding RNase Inhibitor (New England
BioLabs, MA) to the cell-free system following the removal of the RNase-coated beads. The
result was a greater than 70% recovery of initial protein synthesis capability after adding bulkpurified tRNA (Figure 2-3,a, 5th and 3rd bars).
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Figure 2-2 a) Schematic diagram of extract treatment to deplete endogenous tRNA. Ribonuclease
A is covalently attached to superparamagnetic beads. After extensively washing steps to remove
the unattached enzyme, the beads were added to the PMSF-treated extract. Later the treated
extract is separated from the RNase beads and transferred to a new microcentrifuge tube. b) Gel
electrophoresis of purified tRNA from the untreated extract, treated extract for 15min, and Roche
purified-bulk tRNA. The gels showed that the treatment significantly decreases the tRNA level.

Leaching of covalently immobilized RNase A by latent proteases in the extract was
hypothesized to be the cause of RNase A found after removal of the magnetic beads. This
hypothesis was tested by adding a serine-protease inhibitor, phenylmethanesulfonylfluoride
(PMSF), to the cell extract prior to treatment with RNase-coated beads. Adding PMSF (0.5 mM
final concentration) 5 minutes prior to RNase had a similar effect of adding RNase Inhibitor with
greater than 70% recovery of initial protein synthesis capability after adding bulk-purified tRNA
(Figure 2-3,b). The ability to degrade tRNA while maintaining rRNA activity is attributed to a
partial shielding effect of ribosomal proteins [85], and the partial loss of protein synthesis
capability following RNase treatment could be attributed to loss of rRNA function due to RNase
A cleavage. Indeed, longer RNase treatments (30 min, 60 min) resulted in the retention of 58%
and 20%, respectively, of the initial protein synthesis capabilities compared to over 70%
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retention with 15 min of treatment (Figure 2-4,a). However, significant protein synthesis
capabilities of ~300 µg/ml were obtained even with the 60 min treatment.

Figure 2-3 Normalized protein synthesis of sfGFP under various conditions, normalized to the
1.4 mg/ml yield of the control reaction (untreated extract). a) RNase inhibitor addition to the
cell-free protein synthesis at 0.8U/µl reaction restores most of the activity to the 15 min RNase
A-bead treated extract. b) Cell extract incubation with PMSF for 5 min before treatment with
RNAse A beads restores most of the activity to the 15 min RNase A-bead treated extract. PMSF
treated extract does not require RNase inhibitor, which reduces the cost of cell-free protein
synthesis. The error bars represent one standard deviation for n=3.
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2.3.2

tRNA Depletion Efficiency
The tRNA concentrations were further quantified in both treated and untreated extracts

using a qPCR technique via tRNA-specific primers (Table 3-1). Quantification results revealed
that at short treatment times (15 min), significant residual tRNA remained (6-32%), even though
detectable protein synthesis activity had been eliminated (Figure 2-4,b, Figure 2-3). Such
residual tRNA represents inadequate decoupling of the codon-tRNA-amino acid relationship, as
they can compete with heterologous synthetic tRNA resulting in incomplete emancipation and
reassignment.

Figure 2-4 Extent of tRNA-depletion in cell extracts. Colors from light to dark represent mild,
moderate, and strong pretreatment conditions, respectively, throughout. a) Effect of different
treatment severity on protein synthesis capability of the cell extract. Cell extracts were treated for
15, 30, and 60 min for mild, moderate, and strong treatments, respectively. b) Analysis of tRNA
residue of different treated cell extracts with the qPCR technique. The error bars represent one
standard deviation for n=3.
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Increasing the treatment time substantially decreased the residual tRNA. For instance, 30
min treatment of cell extract resulted in a drop of 97% or more in tRNA concentrations for all
targeted tRNAs assessed – Ala(GCC), Arg(CGG), Glu(GAA), Ser(TCG), and Val(GTA). A 60
min RNase A treatment resulted in an average of 99.3% of tRNA degraded for all tRNA assessed,
with greater than 99.5% degradation for Ala(GCC), Arg(CGG), Glu(GAA), and Val(GTA)
tRNA. Previous methods to remove tRNA involving ethanol-Sepharose matrix achieved lower
depletion efficiencies that varied widely for different tRNAs, with an average of 62% depletion
and standard deviation of 28% [77, 84]. In addition, the reported depletion efficiencies were
measured indirectly via protein synthesis activity. Given that cell extracts without detectable
protein synthesis activities can harbor significant residual tRNA (discussed above), the actual
depletion efficiencies could be significantly lower than reported.
The presented method is a significant improvement in consistency and efficacy. Such an
improvement is essential for codon emancipation and reassignment. For example, if 10 codons
are reassigned in a protein 98% of produced product would be correct if only 0.2% of the native
tRNA remained, which is the level of removal reported with Val(GTA) tRNA. However, if 38%
of native tRNA remained and competed for the 10 reassigned codons, less than 1% of produced
protein would be correct. Even at 90% depletion efficiency, the 10% remaining would result in
more than 65% of the product being incorrect for a protein with 10 reassigned codons. Thus, the
high tRNA removal efficiency reported in this paper is essential for facilitating true codon
emancipation for reassignment. Equally important, the reported tRNA emancipated cell-free
system is capable of producing protein at yields (~300 µg/ml) and costs (~$5/mg) that are
reasonable for widespread commercial and research applications [86]. For example, these results
show that the presented method can approximate the near tRNA-free environment of a
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customized PURE system [78], but with higher yields and at a 1,000 fold reduction in cost [86,
87]. In conclusion, quantification of tRNA removal is essential to verifying near 100% tRNA
removal and such an optimized cell-free protein synthesis platform holds great promise for
widespread use of codon reassigned systems.

Figure 2-5 Synthetic tRNA production. a) T7-Hammerhead ribozyme-tRNA DNA construct for
making fMet and Val tRNA. Hammerhead ribozyme cleaves itself exactly at the targeted
position, resulting in the correct tRNA sequence. b) TBE-Urea gel electrophoresis of the in vitro
transcription reactions to produce tRNAs. c) The DNA sequence used for producing fMet and
Val tRNA.

2.3.3

CFPS of Peptides Using Treated Cell Extract and Synthetic tRNA
Previously Cui et al. have demonstrated that tRNA can be synthesized using in vitro

transcription of a T7-promoted tRNA platform [77]. Additionally, Iwane et al. demonstrated the
use of flexizyme to produce functional tRNA, which was used at higher concentrations in the
tRNA depleted PURE system [78]. Here, we briefly demonstrate that synthetic tRNAs are also
compatible with the RNase-treated extract reported above for protein synthesis. To this end,
synthetic tRNAs for fMet and Val were produced with a preceding hammerhead ribozyme to
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yield precise tRNA sequences (Figure 2-5,a) [14, 80]. Synthetic tRNA for fMet and Val were
added at optimized concentrations to produce the designer peptide containing the
formylmethionine and valine (Figure 2-6,a). The synthetic tRNA produced protein at the same
yields as bulk purified tRNA (Figure 2-6,b), demonstrating successful codon emancipation and
use of the system with synthetic tRNA.

Figure 2-6 Emancipating codons using a treated cell extract and synthetic tRNAs. a) The peptide
was designed to contain fMet as starting sequence for the translation process followed by 40 Val
residues, with protein synthesis yield determined using C14-labled Val. b) Cell-free protein
synthesis of the peptide using the 30 min RNase A treated extract. The protein synthesis yields
were normalized based on the control reaction with Roche bulk-purified tRNA (yield of 170
µg/ml). In vitro transcribed synthetic tRNA was added to the cell-free protein synthesis system at
100 µg/ml fMet and 500 µg/ml Val, while the bulk-purified tRNA from Roche was added at 2
mg/ml. The error bars represent one standard deviation for n=3.
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Conclusion
In this study, we developed a robust method to emancipate codons at greater than 99%
efficiencies. This was done by efficiently and affordably degrading native tRNAs of E. coli cell
extracts, which previously had been a key technical challenge. The presented approach resulted
in 2000-fold decreases in native tRNA level compared to untreated extract, while also preserving
protein synthesis activity of the cell extract. Most importantly, the approach maintains high level
protein production (~300 mg/ml) at low cost (~$5/mg) for widespread use.

We also

demonstrated that the treated extract can be used with synthetic tRNAs for protein synthesis.
Overall, codon emancipation is an essential and typically limiting step in codon-tRNA-amino
acid reassignment and holds great promise in expanding proteomic toolset.
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3

ONCONASE PRODUCTION AND A JUST-ADD-WATER CELL-FREE
SYSTEM

This chapter is an adaptation of the paper entitled “Cell-free protein synthesis of a
cytotoxic cancer therapeutics: Onconase production and a just-add-water cell-free system”
published September 2015 in Biotechnology Journal[25], and “Escherichia coli-based cell-free
extract development for protein-based cancer therapeutic production” published April 2016 in
International Journal of Developmental Biology[88]. These works were developed and led by
myself with the help of Mark T. Smith, Anthony M. Bennett, Jacob B. Williams, Conner C. Earl,
Christina Muhlestein, Dr. William Pitt, and Dr. Bradley Bundy.
Biotherapeutics have many promising applications, such as anti-cancer treatments,
immune suppression, and vaccines. However, due to their biological nature, some
biotherapeutics can be challenging to rapidly express and then screen for activity through
traditional recombinant methods. For example, difficult-to-express proteins may be cytotoxic or
form inclusion bodies during expression, increasing the time, labor, and difficulty of purification
and downstream characterization. One potential pathway to simplify the expression and
screening of such therapeutics is to utilize cell-free protein synthesis. Cell-free systems offer a
compelling alternative to in vivo production, due to their open and malleable reaction
environments. In this work, we demonstrate the use of cell-free systems for the expression and
direct screening of the difficult-to-express cytotoxic protein onconase. Using cell-free systems,
onconase can be rapidly expressed in soluble, active form. Furthermore, the open nature of the
reaction environment allows for direct and immediate downstream characterization without the
need of purification. Also, we report the ability of a “just-add-water” lyophilized cell-fee system
to produce onconase. This lyophilized system remains viable after being stored above freezing
for up to one year. The beneficial features of these cell-free systems make them compelling
candidates for future biotherapeutic screening and production.
Introduction
Biopharmaceuticals is a burgeoning 140 billion USD industry and continues to grow [89].
The industry has the potential to improve and save lives by tapping into the vast evolved
diversity and function that nature has to offer. This is epitomized by the success of biological
therapeutics, as 7 of the top 10 grossing prescription drugs are recombinant antibodies or fusion
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proteins [90]. Production and screening systems for recombinant antibodies are considerably
streamlined and continually improving [91]. However, as new non-antibody biotherapeutics are
investigated, production and screening technologies will need to adapt accordingly.
Cancer is the second leading cause of death in the United States, presenting a compelling
target for current and future biologics (CDC, Deaths: Final Data for 2013) [92]. Nonprophylactic anticancer treatments are by definition cytotoxic. Cytotoxic anticancer biologics
may prove difficult to overexpress, scale-up, or screen due to their intrinsically toxic properties.
For example, onconase (ONC) is a known ribonuclease that is in clinical trials for treatment of
malignant mesothelioma and has demonstrated potency against multiple other forms of cancer
[93-95]. However, ONC is derived from the oocytes of the Northern Leopard Frog, which are
time and labor intensive to harvest and culture [96, 97]. Furthermore, downstream evaluation and
screening of ONC requires purification including anion exchange, cation exchange, and finally
size-exclusion chromatography [93].
Attempts at alternative recombinant expression methods for ONC have had limited
success. Producing ONC in the most widely used recombinant expression system, Escherichia
coli, results in the formation of inclusion bodies, requiring laborious purification and refolding
procedures taking three or more days [98]. Although strides have been made to recombinantly
express and secrete ONC in yeasts, these systems also require laborious purification and
concentration steps prior to downstream evaluation and screening [99].
In an effort to circumvent the production limitations of cell-based systems and enable the
rapid contiguous evaluation of the protein, we propose cell-free protein synthesis (CFPS) of
ONC. Cell-free systems feature open reaction environments that can be readily manipulated and
monitored for optimal reaction conditions [2, 100]. Furthermore, CFPS systems are generally
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less sensitive to cytotoxic elements, as there are no cells to keep alive [101]. Recently, the
lyophilization of CFPS reagents has enabled long-term storage at non-ideal temperatures (up to
90 days above freezing), creating a robust “just-add-water” expression system [102]. These traits
make CFPS a compelling alternative for the production and screening of difficult-to-express
biomolecules, such as cytotoxic, insoluble, and membrane proteins [103, 104].
E. coli-based cell-free systems are particularly robust recombinant expression platforms
with reported yields as high as 2.3 mg per mL reaction [105]. These systems have been utilized
to produce diverse products, such as cytotoxic viral proteins, oxygen-sensitive Fe-Fe enzymes,
and therapeutic peptides [101, 106, 107]. Other applications of E. coli-based CFPS have
significantly improved protein solubility and avoided the difficulties associated with inclusion
body formation [108, 109].
Here we demonstrate the robust production of active ONC in E. coli-based CFPS. The
cell-free produced ONC (ONCCFPS) is highly soluble during and after overexpression. ONCCFPS
exhibits similar protein synthesis inhibition and improved anticancer activities compared to in
vivo produced ONC (ONCinvivo). Finally, we show how ONCCFPS could be produced on-demand
by stable and portable lyophilized CFPS systems. We also report the ability of “just-add-water”
lyophilized cell-free systems to be active for up to one year when stored above -80 oC. In short,
cell-free protein synthesis is a robust alternative to produce and screen the difficult-to-express
protein ONC. The ability to rapidly produce soluble, active proteins has implications in
engineering, screening, and producing current and future biotherapeutics. Such technologies will
be essential as medicine becomes more advanced, personal and on-demand.
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Materials and Methods

3.2.1

Cell Growth and Extract Preparation
Cell extracts were prepared as previously described with the following specifications

[109]. Escherichia coli BL21-Star™ (DE3) (Invitrogen, Carlsbad, CA) were grown serially from
glycerol stocks at 37 oC and 280 rpm as follows: 5 mL LB media overnight, 100 mL LB media
until an OD600 of 2.0, and 1 L 2YT media. Growths were induced by addition of 1 mL 1 M
isopropyl-1-thio-β-D-galactopyranoside (IPTG) at OD600 0.4-0.7 and monitored until the end of
log-phase growth. Cells were harvested by centrifugation at 6000 xg, 4 oC for 15 mins and
subsequently washed with Buffer A (10 mM Tris-acetate, 14 mM magnesium acetate, 60 mM
potassium glutamate, 1 mM dithiothreitol, pH 8.2). Cells were again centrifuged as before,
resuspended in 1 mL Buffer A per gram wet cells, and lysed as previously described [109].
Lysates were centrifuged for 30 mins at 16000 xg, 4 oC. The supernatant was removed,
aliquotted, flash frozen with liquid nitrogen, and stored at -80 oC until use. Lyophilized extracts
were prepared as previously described [102].

3.2.2

In Vivo Expression
Recombinant onconase gene (NCBI Accession# 1PU3_A) was codon optimized and

custom synthesized (DNA 2.0, Menlo Park, CA) for improved expression in Escherichia coli.
The optimized gene was cloned into the T7-promoted expression plasmid pJ411-KanR with a
Q2E mutation and C-terminal 6xHis tag, resulting in plasmid pJ411-Onc.
Escherichia coli BL21-Star™ (DE3) was transformed with pJ411-Onc. Cells were grown
serially as described above with the following specifications. The final stage of cell growth was
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in 1 L Terrific Broth media. Growths were induced at OD600 0.4-0.7 by addition of 1 mL 1 M
IPTG and grown overnight. Cells were harvested, washed, and lysed as above. ONCinvivo was
purified from inclusion bodies in the cell lysate pellet and refolded as previously described [110].
To verify the molecular mass, ONCinvivo was desalted and analyzed using an Agilent
Technologies 6230 TOF LC/MS (Agilent, Palo Alto, CA).

3.2.3

Cell-free Protein Synthesis
Cell-free protein synthesis (CFPS) ONC production was performed using the PANOxSP

system, as previously described [102]. Reactions were performed for 3 hours 15 mins at 37 oC.
Production yields were calculated by incorporation of radiolabeled C14-Leucine, as previously
described [83]. Yields from CFPS reactions diluted during the reaction incubation were
calculated based on the initial reaction volume (IRV). CFPS reactions for protein synthesis
inhibition assays were performed without dilution. Reaction volumes were scaled between 50 µL
and 1 mL with no observable change in yield.

3.2.4

Onconase Anticancer Activity Assay
To assay the anticancer properties of ONC, we measured the cell viability of breast

cancer cells (MCF7) using an MTT [3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium
bromide)] assay [111]. MCF7 cells were grown in Dublecco’s Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. Once confluent,
cells were trypsinized (trypsin-EDTA 0.05%) and plated into a clear culture-grade 96-well plate
at 3000 cells per well and grown for 24 hours in 100 µL fresh media. Before treatment, the
growth media was replaced with 100 µL fresh media, treatment sample, and up to 50 µL PBS
(pH 8.0) for a total well volume of 150 µL. After 48 hours incubation, treatment solution was
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aspirated, wells were washed with 200 µL PBS, and finally filled with 90 µL fresh media and 10
µL of 5 mg per mL MTT in PBS. After 4 hours incubation, MTT solution was aspirated and
replaced with 75 µL DMSO. The plate was incubated for 15 minutes at room temperature and
absorbance was measured at 540 nm with background absorbance of 720 nm subtracted.

3.2.5

tRNA Purification
Total RNA was purified from BL21-Star™ (DE3) extract using two rounds of acid

phenol:chloroform:isoamyl alcohol (Ph:Chl:IA) 125:24:1 extraction as follows. Ph:Chl:IA was
added to one volume of extract, vigorously vortexed, and centrifuged at >16,000 xg, 4 oC for 30
mins. After centrifugation and transferring the aqueous phase to a new tube, a mix of
sample:isopropyl alcohol:8M ammonium acetate 100:145:45 by volume was used to precipitate
total RNA, and the pellet was washed with cold 95% and 70% ethanol. The alcohol precipitation
and wash were repeated two times. The resulting pellet was dissolved in a mixture of 0.73 M
LiCl, 10 mM sodium acetate pH 4.5 to precipitate large RNA. The tRNA remained in the
supernatant, and was precipitated and washed using the above described alcohol protocol. The
pellet was resuspended in RNase-free water and purity was checked using 260/280 nm
absorbance ratio and TBE-Urea PAGE gel. In the case of using TRIzol® (Life Technologies),
Trizol was used instead of phenol:chloroform:isoamyl alcohol.
Reagent cost calculations were based on previous calculations and on reagent prices
obtained from the 2015 online catalogues of Roche Applied Sciences, Sigma-Aldrich, VWR,
Zymo Scientific, and Life Technologies [86]. Cost of labor was not included.
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Results
The protein onconase (ONC) of the RNase A superfamily is a promising biotherapeutic
to target multiple forms of cancer. ONC, like other RNases, is difficult to overexpress
recombinantly and poses difficulties for overexpression in the endogenous cell-line. Some of the
difficulties include cytotoxic activity, ribonuclease activity, and the formation of inclusion
bodies. We compare E. coli-based in-vivo produced ONC (ONCinvivo) to CFPS produced ONC
(ONCCFPS) in terms of solubility and activity. We demonstrate that CFPS is a valuable platform
to rapidly produce and directly screen this biotherapeutic.

3.3.1

Recombinant In Vivo Synthesis of Onconase
The ONC gene was designed for optimal T7-promoted Escherichia coli expression. The

resulting pJ411-Onc plasmid was transformed into BL21-Star™ (DE3) cells. Cells were cultured
and induced with 1 mM IPTG 2.5 hours after inoculation (OD600 0.4-0.7, Figure 3-2, A). The invivo-produced onconase was verified using mass spectrophotometry (Figure 3-1).
Control cells harboring the non-toxic pJ411-MbRS (Methanosarcina barkeri pyrrolysylsynthetase) were cultured identically. MbRS was chosen as a control, as it is also known to form
inclusion bodies. Induction with IPTG resulted in a premature transition out of exponential phase
for both growth types (Figure 3-2, A). The transition is expected, as energy is diverted from cell
growth to protein overexpression and IPTG is a known toxin for Escherichia coli [112]. The
growth of cells harboring the ONC gene slowed beyond that of the nontoxic MbRS gene (pvalue = 0.0227), implying the toxic action of ONC may inhibit growth until the toxic protein
precipitates or is otherwise inhibited.

33

Figure 3-1 Mass spectrometry analysis of in-vivo expressed onconase. In vivo produced, purified,
and refolded onconase was prepared for mass spec using C-18 desalting columns. Onconase was
analyzed using an Agilent 6200 Series TOF LC/MS. The observed peaks correspond to the
expected molecular weight of onconase (12772 Da).

Figure 3-2 Onconase In vivo Expression and Solubility. A) Growth Rate of Escherichia coli
harboring plasmids pJ411-ONC or pJ411-MbRS, both genes known to produce inclusion bodies.
Growths were induced with IPTG (+) or not induced (-). Graphed curves represent growth
regression curves (Table 3-1). After induction (ONC+ and MbRS+), the growth rate slowed.
ONC+ growth rate became nearly static 1 hr after induction, which is consistent with the
cytostatic/cytotoxic nature of ONC. B) Electrophoretic analysis of total, soluble, and inclusion
body fractions of ONC+ growth. The overexpression band is visible only in the total and
inclusion body fractions. No soluble ONC was detected. (error bars represent 95% confidence
interval of regression).
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Table 3-1 contains the constants for the Verhulst-Pearl Equation after fitting this equation
to our data. This equation is commonly used to model cell population growth and is below
𝑃𝑃(𝑡𝑡) =

𝑘𝑘𝑃𝑃𝑜𝑜 𝑒𝑒 𝑟𝑟𝑟𝑟
𝑘𝑘+𝑃𝑃𝑜𝑜 (𝑒𝑒 𝑟𝑟𝑟𝑟 −1)

( 3-1)

Table 3-1 Bacterial Growth Regression Curves
M. barkeri Pyryl-Synthetase (MbRS)

Onconase
IPTG
Induced

Not
Induced

IPTG
Induced

Not
Induced

P0

0.007

0.013

0.022

0.013

k

1.70

5.45

2.35

5.69

r

2.01

1.52

1.41

1.48

R2

0.996

0.993

0.978

0.979

0.995

0.992

0.973

0.974

Adjusted R2

In this case, P0 was unknown due to the nature of the growth. Therefore, we included P0
as a constant to be fitted. We calculated adjusted R2 (coefficient of determination) which are
displayed in the table above. ANOVA analysis of the induced growth curves reveals a
statistically significant difference between the MbRS and ONC growths (p-value < 0.022).
Previous works report the formation of inclusion bodies during recombinant bacterial
expression of ONCinvivo [98]. To assess expression and formation of inclusion bodies, crude and
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centrifugation-clarified lysates were run on SDS-PAGE (Figure 3-2, B). Protein overexpression
bands appear in the crude lysate and not in the clarified lysate, indicating the low solubility of
ONCinvivo. Indeed, densitometric analysis of the expression bands indicate that less than 1% of
the ONCinvivo remains soluble (Figure 3-2,B).
ONCinvivo protein with potent nuclease activity was produced only after steps of inclusion
body purification, washing and refolding (a 3+ day process, Figure 3-3). While the purity of the
ONCinvivo was greater than 90%, the post-fermentation purification steps are time consuming,
expensive, and challenging to scale-up, thus restricting the feasibility of high-throughput
screening and inexpensive production scale-up. To overcome the difficulties of in vivo
production of ONC, we assessed the effectiveness of a cell-free approach.

Figure 3-3 Nuclease Assay with In vivo-produced Onconas. Onconase nuclease activity was
assayed directly using RNAseAlert® substrate. Sample was added to 40 nM substrate in a 96well plate with a final well volume of 100 µL. Reactions were incubated for 1 hour at room
temperature. The cleaving of the substrate was measured by observing fluorescence at 480/520
nm excitation/emission.
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3.3.2

Cell-free Synthesis of Onconase
ONC was produced in cell-free protein synthesis (CFPS) from the identical plasmid as in

vivo and assayed for yield and solubility (Figure 3-4,A). Initial yields from a standard CFPS
reaction were less than 3% of the reference protein Green Fluorescent Protein (GFP) yields (0.03
mg per mL ONCCFPS versus 1.45 mg per mL GFPCFPS). However, and notably, greater than 80%
of the ONCCFPS yield was soluble, representing a greater than 80-fold increase of percent soluble
yield over in vivo expression. If the soluble protein is active, its production would unleash the
protein’s nuclease activity, likely degrading the machinery used to produce it and leading to
lower overall yields. ONC predominantly targets tRNA and can also degrade mRNA and rRNA
[113]. We hypothesized that if the soluble product was active, low yields would be due in part to
tRNA degradation.
In principle, the inhibition of ONCCFPS during production would improve overall yields
by protecting essential RNA machinery for protein synthesis. However, one of the features of
RNase A-like ONC is its ability to resist inhibition by RNase A inhibitors, specifically at
physiological salt concentrations [114]. This resistance is thought to provide ONC its beneficial
anticancer properties, allowing the RNase to function after endocytosis despite the potential
presence of RNase inhibitors [110, 115]. Accordingly, when we added a potent RNase A
inhibitor (RNase Inhibitor, Murine; New England Biolabs, MA) to our CFPS productions for
ONCCFPS, we observed no improvement in overall yields compared to standard CFPS (Figure
3-4,B, RNase Inhibitor).
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Figure 3-4 Cell-free Expression Optimization of ONC. A) Abbreviated scheme of CFPS
production for direct downstream applications. B) Modified CFPS methods in attempts to
improve ONCCFPS yields by RNase inhibition and tRNA addition. tRNA was added as a single
bolus (+tRNA t0) or dosed throughout the reaction at specific intervals (+tRNA t0-tn). C) CFPS
optimization of ONCCFPS yields through the addition of tRNA at specified intervals and volumes
by percent of initial reaction volume (%IRV). ONCCFPS yields were directly correlated to total
tRNA addition per mL of initial reaction volume (tRNA [mg/mL]). Soluble yield percentage (X)
were >80% for all ONCCFPS. (n>=3, error bars represent 1 standard deviation).

We hypothesized that the replacement or supplementation of tRNA would improve
overall ONCCFPS yields by mitigating tRNA-degradation effects. The open nature of CFPS
makes possible the addition of excess tRNA without need to modify the expression organism.
Harnessing this feature, CFPS was performed while providing additional purified tRNA.
Addition of an initial bolus of tRNA (96 mg tRNA per mL initial CFPS, dilution with 1.92
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volumes) effectively eliminated ONCCFPS production (Figure 3-4,B, +tRNA t0). One possible
cause of this inhibitory effect may be due to excessive deacylated tRNA. Previous work has
reported that excessive deacylated tRNA can inhibit binding of amino acyl-tRNA at the
ribosome P site [116]. In the case of adding excess tRNA at the start of the reaction, it can be
postulated that a majority of tRNA remain non-acylated due to the limited supply of amino acids
and aminoacyl synthetases.
As an alternative approach, the same amount of tRNA was added to the CFPS reaction at
15 minute time intervals throughout the reaction, resulting in a >7-fold yield improvement
(Figure 3-4,B, +tRNA t0-tn). To further optimize yields, the system was modified by adding a
range of 12-384 mg total tRNA per mL initial CFPS. Stock concentrations of tRNA were 25, 50,
100, or 200 mg per mL in water. Time intervals were every 15 or 30 minutes. Volumes added at
each time interval were 4, 8 or 16 percent of the initial reaction volume (%IRV). We observed
ONCCFPS yield was directly proportional to the amount of tRNA added to the reaction and not
effected by dilution within the employed range of %IRV (4-16 %IRV at each interval) (Figure
3-4,C). For example, yields were statistically indistinguishable when a total of 48 mg per mL
CFPS was added, regardless of %IRV.
In the best case, ONCCFPS production increased greater than 56-fold (from standard CFPS
of 0.03 to 1.86 mg per ml for the conditions 384 mg total tRNA per mL CFPS, 15 min tRNA
addition interval, 16% IRV). This increase in total yield was matched in increased soluble yield.
In all cases when reactions were supplemented with tRNA at 15 min intervals, the solubility of
ONCCFPS remained above 95% of total yield.
The best ONCCFPS yield outperformed our reference protein (GFP) in standard CFPS by
28%. The addition of supplemental tRNA to CFPS producing onconase linearly improved yields.
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To verify this effect was not due to the lack of tRNA in CFPS, we performed CFPS of an
expression-optimized GFP gene. tRNA was added at multiple concentrations at the beginning of
CFPS reaction without dilution (Figure 3-5, A). The addition of tRNA at the initiation of CFPS
appears to slightly improve yields, however the improvement is not statistically significant and
fails to reject the null hypothesis of no difference in mean yield (p-value = 0.87). Periodic
addition of tRNA to CFPS (15 min interval, 16% initial CFPS reaction volume [IRV], 48 mg
tRNA per mL IRV) caused GFP yields to drop by >50% (Figure 3-5, B). One possible cause of
this protein synthesis inhibition is the inundation of the reaction environment with deacylated
tRNA, which can compete for the ribosomes’ p-site (i.e. entry site of tRNA into the translation
process) [116]. The competition between acylated- and deacylated-tRNA would potentially be
eliminated or mitigated in CFPS of ONC, due to the degradation of excess tRNA by ONCCFPS.

Figure 3-5 Green Fluorescent Protein CFPS. A) The addition of tRNA to the CFPS reactions of
GFP doesn’t produce significant different in final protein production level. B) The addition of
large amount of tRNA at the beginning of the reaction inhibit the CFPS of GFP.
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The open nature of CFPS provides the control required to modify the translation
environment for ONCCFPS production. The periodic addition of tRNA secures sufficient tRNA
for translation processes essential during ONCCFPS expression. Moreover, excess tRNA may act
as sacrificial RNA and provide fodder for endogenous E. coli RNases and ONCCFPS present in
the reaction, aiding in the preservation of essential translational RNA (mRNA encoding ONC
and rRNA). Furthermore, adding doses of tRNA throughout the CFPS reaction mitigates any
inhibition that excessive deacylated tRNA may have on the ribosome. These effects make our
modified CFPS a propitious system for rapid ONC expression.
One key component of biotherapeutics is the ability to scale-up production. Our and
other’s previous work have reported that CFPS is readily scaled, from as little as 15 µL to 100 L
[23, 117]. To verify that our modified CFPS setup would also scale, we produced ONCCFPS with
initial reactions volumes of 50 and 1000 µL. To maintain consistent heat and mass transfer, total
reaction volume never exceeded 3 mL in 50 mL conical centrifuge tubes and the tubes were
shaken at 280 RPMs. Small and large scale reactions produced ONCCFPS equally well (Figure
3-6), indicating our modified CFPS system may work for larger scale as long as reaction
engineering principles are considered. Scaling from 50 to 1000 µL increased yield by 10%,
indicating this 20-fold scale-up was not deleterious to the modified CFPS.

3.3.3

tRNA-supplemented Cell-free Protein Synthesis
While the production of ONCCFPS can be increased in CFPS systems by adding

supplementary tRNA, this improvement is beneficial particularly if overall costs per yield
decrease. We have previously described the costs of our standard cell-free system [86]. To
analyze the impact of tRNA costs due to addition of tRNA, we considered 3 methods of
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procuring tRNA: 1) commercially purchased tRNA (Roche, MRE600), 2) tRNA purified with a
standard commercial kit (TRIzol®, Life Technologies), and 3) tRNA purified with an in-house
phenol-chloroform extraction method, detailed in Materials and Methods. Purification costs
included all reagents’ costs (cost of kit components, cost of consumable materials for cell growth,
lysis, and purification). Purified tRNA were verified to have similar or better activity per mg in
the CFPS reaction than the commercially purchased material (Figure 3-7). The tri-reagent
purified tRNA performed at about 80% of the commercial tRNA. The in-house purified tRNA
allowed for an increase in total yields of about 15% of the commercial tRNA.

Figure 3-6 CFPS Reaction Volume Scale up for onconase production.
Although convenient and effective, the expense of commercially purchased tRNA
outweighed the benefit (Figure 3-8, B). Indeed, the use of this tRNA increased the costs per mg
ONCCFPS by an average of 110% over standard CFPS. Alternatively, the commercially purchased
tri-reagent was effective at providing tRNA at about 45% the expense of the commercially
purchased tRNA. This price represented a break-even price-point: the average cost per mg
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ONCCFPS remained nearly level, regardless of tRNA addition. While there is not a yield cost
reduction associated with adding commercial or tri-reagent purified tRNA, their addition to the
CFPS reactions did significantly improve the yield of ONC per volume, which simplifies and
decreases the costs of downstream assays without further treatment.

Figure 3-7 CFPS with Commercial and Purified tRNA.

To further reduce the cost per mg ONCCFPS produced, we developed an in-house phenolchloroform extraction procedure based on the same principles as the commercial tri-reagent. The
optimized procedure was effective at reducing the cost of tRNA by greater than 92% compared
to the commercially purchased tRNA. The 13-fold reduction in tRNA cost caused overall yield
costs to decrease asymptotically from ~115 USD towards ~20 USD per mg ONCCFPS produced
(Figure 3-8, A). This 5-fold reduction in ONCCFPS production costs and 56-fold increase in yield
was achieved by 1) the direct replenishment of tRNA afforded by the cell-free system and 2) the
development of an in-house optimized tRNA purification method.
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3.3.4

Lyophilzed Cell-free System
We have previously demonstrated the ability of CFPS to be stabilized up to 90 days by

lyophilization, as outlined in the scheme of Figure 3-9,A [102]. Utilizing this lyophilized CFPS
(lyo-CFPS) to produce biotherapeutics is a promising method for rapid, mobile and on-demand
therapeutics. The robust stability of lyo-CFPS is characterized by its ability to outperform
standard aqueous extracts after storage at temperatures above -80 oC (Figure 3-9).
Our previous report included stability data up to 90 days in storage. Figure 3-9,C reports
for the first time the viability of lyo-CFPS stored for 1 year. The standard extract lost all
observable protein synthesis viability under all storage conditions except at -80 oC. In stark
contrast, the lyo-CFPS retained protein synthesis viability under all storage conditions except
after 1 year at 25 oC. We tested our lyo-CFPS system against the standard CFPS to produce
ONCCFPS. The lyo-CFPS performed equally well or better under standard CFPS and upon
addition of tRNA (Figure 3-9,B). The robust stability of lyo-CFPS lays the fundamental
framework for applications in stabile, mobile, and “just-add-water” biotherapeutic expression.

3.3.5

Onconase Activity
The methods we describe for CFPS production of ONC can reduce costs while providing

for direct expression of soluble, accessible proteins ready for downstream characterization and
applications. To demonstrate the direct downstream assessment, we analyzed our ONC by 1)
cell-free protein synthesis inhibition assay and 2) cancer cell inhibition assay.
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Figure 3-8 CFPS ONC Yield costs. A) ONCCFPS was produced with increasingly concentrated
doses of tRNA. Yields (x) were directly proportional to the amount of tRNA added. The yield
cost (US dollars per mg ONCCFPS, ■) is calculated based on the in-house produced tRNA. B)
Table of prices and purities of tRNA sources.

3.3.6 Protein Synthesis Inhibition Activity
Protein synthesis inhibition is an indirect measurement of the nuclease activity of ONC
and likely plays a key role in the anticancer action. Nuclease activity of cell-free produced
ONCCFPS was evident by the increase in protein yield when dosed with tRNA over time. To
confirm this effect in controlled conditions, we produced GFP in the presence and absence of
ONC. ONC was added at the initiation of CFPS reactions. The addition of ONCinvivo resulted in
an inhibitory concentration of 50% of protein synthesis (IC50) at 5.3 ± 1.1 µM (Figure 3-10 A, B).
The addition of ONCCFPS resulted in an IC50 of 11.2 ± 3.9 µM , while negative CFPS controls
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without ONC did not inhibit protein synthesis as severely (Figure 3-11). CFPS allowed for
immediate downstream analysis of ONCCFPS protein synthesis inhibition.

Figure 3-9 Lyophilized CFPS Systems. A) Scheme of lyophilized CFPS system. B) ONC yield
comparison between standard aqueous extracts and lyophilized extracts. C) Extract stability data
for extracts stored for up to 1 year under specified temperature conditions. Data up to 90 days
was reported previously (Smith et al. 2014a). The cell-extract utilized for lyophlization was not
initially as active as the cell-extract used in Figure 3-4, which accounts for the difference in
baseline GFP expression levels. (n=3, error bars represent 1 standard deviation).

To verify that the CFPS solution was not responsible for the observed protein synthesis
inhibition or cancer cell inhibition, CFPS reactions devoid of genes (CFPS NEG) and CFPS with
non-toxic gene Q[beta] coat protein (CFPS Neg (Qbeta)) were added at identical dilutions to
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each assay as reported in Figure 3-11. CFPS NEG generally enhanced the viability rather than
inhibiting. CFPS NEG (Qbeta) did inhibit the synthesis of GFP, which inhibition may be due to
ATP:ADP ratio changes caused by the addition of relatively large volumes of used CFPS
reaction solution. Importantly, CFPS solution containing ONCCFPS was distinguishably more
active at inhibiting GFP synthesis than CFPS NEG (Qbeta). In the cases when CFPS Neg
inhibited, such as with the MTT assay for 2150 and 3000 nM, the exclusion of these data points
for calculating the IC50 of ONCCFPS actually lowered the calculated value. Thus, these data were
included in the analysis of the anticancer IC50 of ONCCFPS.

Figure 3-10 Onconase Activity Assays. A) ONC was added to CFPS of GFP to assay its ability
to inhibit protein synthesis. B) Protein Synthesis IC50 of ONCCFPS and ONCinvivo. C) Breast
cancer cells (MCF-7) were treated ONC to assay its ability to inhibit and kill cells. D) Cancer
cell viability IC50 under treatment with control doxorubicin, ONCCFPS, and ONCinvivo. (n=3, error
bars represent 1 standard deviation, IC50 ranges represent 95% confidence interval).
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3.3.7

Anticancer Activity
One of the promising characteristics of ONC is its potential as an anticancer therapeutic.

To validate our ONC was active against cancer cells, we tested our CFPS and in vivo produced
protein against the breast cancer cell line MCF-7 using an MTT cell viability assay, which
quantifies the mitochondrial activity after a specified treatment period. As a baseline comparison,
we performed the assay with doxorubicin and observed an IC50 = 0.17 ± 0.07 µM DOX,
consistent with previously published results (Figure 3-12) [111].

A

B

Figure 3-11 Protein Synthesis and Cancer Cell Inhibition Controls. A) Effect of different positive
and negative controls on CFPS of GFP.; B) effect of positive and negative controls on cancer cell
viability.

The treatment of the cancer cells with ONC reduced cell viability by upwards of 95%.
The IC50 of ONCinvivo was consistent with previously published results at 6.48 ± 1.44 µM (Figure
3-10, C, D) [118]. Of considerable note, the IC50 of ONCCFPS was about 60 times lower than
ONCinvivo at 0.11 ± 0.046 µM, while the addition of CFPS negative control reaction generally
maintained or improved the overall viability of the cells (Figure 3-11). The lowered IC50 of
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ONCCFPS suggests it may be more potent than ONCinvivo or the CFPS reaction mixture may act as
an adjuvant for the endocytosis of ONC.

Figure 3-12 The MCF7 cancer cell line was subjected to a doxorubicin control for an MTT cellviability assay. The resulting IC50 at 48 hours was 0.17 ± 0.07 µM. This is consistent with
previously published IC50 at 72 hours of 0.1 µM [111].
Discussion
CFPS production directly to downstream assay (protein synthesis inhibition and
anticancer assay) without purification or refolding dramatically reduces the time from gene to
meaningful data. This system, together with the ability of CFPS to express genes directly from
PCR-produced linear expression templates, lays the foundation for high-throughput technologies
to screen large libraries of characterized and uncharacterized proteins for anticancer properties.
Such a high-throughput method may reduce research investment of time and money towards
future cancer therapies and, in turn, reduce cancer treatment expense to the patient. These CFPS
techniques have the potential to also be adapted for other difficult-to-express proteins and
biological complexes, such as DNA-protein fusions.

49

We demonstrated the cell-free protein synthesis system’s ability to produce a cytotoxic
anti-cancer therapeutic, ONC. We have shown that with inherent open nature of cell-free system,
we can freely modify, replace, and supplement the system towards making the final product in a
highly soluble and active form without the need of specialized cell lines or complex mutagenesis.
With our system, the ONC yield can be increased by 56-fold compared to standard CFPS with
greater than 95% solubility. This system can open unique opportunities for making other
difficult-to-express biotherapeutics. In addition, CFPS is a promising platform for biopharma
high-throughput that can save time and expense, and it can be easily scaled for making
commercial or personalized drugs, however cost-effectiveness comparing scaled CFPS to
traditional in vivo scale-up would need to be analyzed for each individual biotherapeutics
produced.
The robust and stable nature of lyophilized cell-free systems provides further benefit to
the production of biotherapeutics. We demonstrated that lyophilized cell-free system was
comparable to aqueous CFPS at producing ONC. Furthermore, Lyo-CFPS retains its viability
longer under non-ideal storage conditions. Thus, lyophilized extract can enable CFPS to become
a platform for mobile biopharma applications, such as lab-on-a-chip, by just adding water to the
system.
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4

A CELL-FREE PROTEIN SYNTHESIS APPROACH TO BIOSENSING HTRβSPECIFIC ENDOCRINE DISRUPTORS

This chapter is an adaptation of the paper entitled “Cell-Free Protein Synthesis Approach
to Biosensing hTRβ-Specific Endocrine Disruptors” published February 2017 in Analytical
Chemistry, ACS Publication[119]. This work was developed and led by myself, Miriam J.
Shakalli Tang, and Mark T. Smith with the help of Jeremy M. Hunt, Robert A. Law, Dr. David
Wood, and Dr. Bradley Bundy. This work was a collaboration between our lab and Dr. Wood’s
lab at Ohio State University (OSU). Miriam Shakalli, Robert Law, and Dr. David Wood are
affiliated with OSU.
Here we introduce a Rapid Adaptable Portable In-vitro Detection biosensor platform
(RAPID) for detecting ligands that interact with nuclear hormone receptors (NHRs). The RAPID
platform can be adapted for field use, allowing rapid evaluation of endocrine disrupting
chemicals’ (EDCs) presence or absence in environmental samples, and could also be applied to
drug screening. The biosensor is based on an engineered, allosterically-activated fusion protein,
which contains the ligand binding domain from a target NHR (human thyroid receptor β in this
work). In vitro expression of this protein using cell-free protein synthesis (CFPS) technology in
the presence of an EDC leads to activation of a reporter enzyme, reported through a
straightforward colorimetric assay output. In this work, we demonstrate the potential of this
biosensor platform to be used in a portable “just-add-sample” format for near real-time detection.
We also demonstrate the robust nature of the cell-free protein synthesis component in the
presence of a variety of environmental and human samples, including sewage, blood, and urine.
The presented RAPID biosensor platform is significantly faster and less labor intensive than
commonly available technologies, making it a promising tool for detecting environmental EDC
contamination and screening potential NHR-targeted pharmaceuticals.
Introduction
Biosensors can be life-changing devices, with uses ranging from daily glucose
monitoring for diabetes patients to the rapid detection of toxins in the environment[120, 121].
When biosensors provide the required degree of specificity and sensitivity in combination with
more rapid assay times, they are excellent alternatives to traditional detection methods[122].
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Biosensing systems are available in various formats, from cell-based systems with complex
metabolic pathways to less complex in vitro systems. Cell-based systems can have a broader
spectrum of detection capabilities, however, they are hindered by transmembrane transport
limitations, the need to maintain cell viability and stability, time-consuming preparation, and
protracted assay times[123, 124]. In contrast, in vitro methods are commonly faster, more
straightforward, simpler to store, and less expensive. Here we present a versatile, near-real time
in vitro biosensor for detecting ligands that bind nuclear hormone receptors (NHRs).
NHRs help regulate vital functions of the cells and organisms, such as metabolism,
homeostasis, differentiation, development, and reproduction[38, 39, 47]. NHRs interact with
many natural and synthetic ligands and about 4% of all currently marketed therapeutics interfere
with the activity of one or more NHRs[40]. NHRs also can interact with environmental
endocrine disrupting chemicals (EDCs), which have become a public safety concern due to their
ability to disrupt naturally occurring endocrine control. EDCs affect the endocrine system in
humans and animals, commonly by mimicking natural hormones and binding to specific NHR
ligand binding domains[46]. Examples of these include medical and industrial xenoestrogens,
such as diethylstilbestrol and bisphenol-A, as well as naturally occurring phytoestrogens, such
and genistein and daidzein[47-49]. EDCs have been found in common dietary, environmental,
and household chemicals and have been linked to diverse diseases and disorders, including
multiple cancers, developmental disorders, and other epigenetic dysfunction[43, 44].
Unfortunately, due to their large numbers, most chemicals and mixtures in commerce worldwide
remain largely uncharacterized for endocrine disrupting activity[45].
In order to deliver faster detection of NHR-ligand interactions, we previously developed
an EDC biosensor platform where the presence of an EDC is reported through a change in
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growth phenotype of an engineered Escherichia coli strain[125, 126]. This platform relies on a
multi-domain engineered allosteric fusion protein, which reports ligand binding to a given NHR
through the activation of a fused thymidylate synthase reporter enzyme (Figure 4-1,A). In
practice, the biosensor protein is constitutively expressed in an engineered E. coli thymidineauxotroph strain, leading the growth phenotype of the strain to be dependent on the presence of
an NHR-targeting ligand. Binding of the ligand to the NHR ligand binding domain activates the
thymidylate synthase reporter enzyme and enables cell growth, allowing the presence and
activity of a specific NHR ligand to be readily ascertained by a simple turbidity measurement
after overnight incubation. An inserted mini-intein splicing domain has also been included to
stabilize the fold of the NHR, and provide a conduit for the ligand-binding signal to the reporter
protein. A critical aspect of this multi-domain biosensor protein is that it is modular, potentially
allowing new biosensors based on alternate human and animal NHRs to be generated by
swapping NHR ligand binding domains embedded in the intein domain scaffold[127-129].
However, the system still relies on bacterial growth phenotypes for activity quantification, and
thus requires a minimum overnight incubation to produce a sufficient signal. Also, this assay and
other cell-based assays (i.e. bacterial, yeast, and mammalian) for detecting NHR-binding ligands
can be affected by the presence of cytotoxic chemicals in samples and poor cellular uptake rates.
In this work, we introduce the Rapid Adaptable Portable In-vitro Detection biosensor
(RAPID). This assay system combines our existing multi-domain biosensor protein design with
rapid and efficient CFPS technology to overcome specific limitations of both in vitro and cellbased assays[56, 130-132]. In this system, the biosensor fusion protein is expressed using a
CFPS system in the presence or absence of an unknown EDC sample. An engineered reporter
enzyme domain on the biosensor protein exhibits ligand-dependent activity, resulting in a simple,
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colorimetric readout. Unique CFPS characteristics, including its chemically accessible reaction
environment, robustness, scalability, and control[88, 132, 133], make this technology a powerful
biosensing platform for both simple and complex detection applications. In addition, the ability
to lyophilize the CFPS components enables this type of biosensor to be stockpiled for
emergencies and biothreat situations. Further, the robustness of the sensor design and simplicity
of its visual readout could facilitate field-deployment, where assays of environmental samples
could be carried out by minimally trained personnel in the absence of any conventional
laboratory equipment. By leveraging the advantageous traits of CFPS, we have generated a
highly practical and effective CFPS biosensor for uses in detecting toxic EDCs, as well as
potentially valuable therapeutics against this important drug target class.

Experimental Section

4.2.1

Materials
The ligands used for this paper, 3,3’,5-tiiodothyroacetic acid (TRIAC, 95%), 17-β-

estradiol (E2), and 3,3′,5-triiodo-l-thyronine sodium salt hydrate (T3, 95%), were purchased from
Sigma-Aldrich.

4.2.2

Biosensor Design and Construction
The pET-based plasmid encoding the biosensor protein (MBP-IN-hTRβ-IC-βlac as

illustrated in Figure 4-1,A) is based on our previously reported biosensor design for thyroid
receptor (TR) ligands[127]. The biosensor fusion protein was inserted into the DHFR control
plasmid supplied with the PureExpress® In Vitro Protein Synthesis Kit (New England Biolabs),
which includes a T7 promoter to regulate expression of the target protein. Construction of the
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biosensor gene was accomplished by stepwise insertion of DNA segments encoding the maltosebinding domain (MBP), the intein-human TR fusion module (IN-hTRβ-IC), and the β-lactamase
reporter protein (β-lac), where the resulting biosensor fusion gene replaces the DFHR expression
control gene. In this case, the MBP was taken from the commercially available pMal-c2
expression vector (New England Biolabs), the IN-hTRβ-IC segment was taken from our
previously reported TR biosensor plasmid[127], and the

β-lac

reporter protein was taken from a

previously reported intein fusion expression plasmid[134].

4.2.3

Cell Extract Preparation
Cell extract preparation was performed as previously described[135]. Briefly, 5 ml of LB

media was inoculated using E. coli BL21.DE3* strain in a cell culture tube. The culture was
incubated overnight at 37 °C while shaking at 280 rpm. The culture was transferred to 100 ml
LB media and upon reaching OD 2.0, it was transferred to 1 liter LB media in a Tunair flask. T7
RNA polymerase was overexpressed by inducing the culture with 1 mM isopropyl β-D-1thiogalactopyranoside (IPTG) at OD 0.6. The cells were harvested at the end of the exponential
phase by centrifugation at 6000 RCF for 10 min at 4 °C. The cells were washed by suspending in
pre-chilled Buffer A (10 mM Tris-acetate pH 8.2, 14 mM magnesium acetate, 60 mM potassium
glutamate, and 1 mM dithiothreitol (DTT)), and subsequently centrifuged at 6000 RCF for 10
min 4 °C. The cells were resuspended in 1 ml Buffer A per gram cells and homogenized using
EmulsiFlex French Press homogenizer at 20000 psi. The lysate was clarified by centrifugation at
12000 RCF for 30 min at 4 °C. The supernatant was incubated at 37 °C for 30 min while shaking
at 280 rpm, flash frozen in liquid nitrogen, and then stored at -80 °C for later use as cell extract
for CFPS.
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4.2.4

Lyophilizing the Biosensor System
For lyophilized biosensor systems, CFPS reagents were mixed and lyophilized as

described previously[102, 136] with slight modifications including that all reagents necessary for
CFPS were combined and lyophilized together. Briefly, CFPS components were added to a prechilled tube in the following order while the tube rested on the ice: deionized water, magnesium
glutamate, PANOxSP, and lastly the plasmid. The reaction mixture was mixed gently and
transferred to a 1.5 ml Eppendorf tubes in 250 µl aliquots. Tubes were quickly placed into a
liquid nitrogen container to flash freeze the reaction. The samples were lyophilized using
FreeZone 2.5 Liter Benchtop Freeze Dry System (LABCONCO, Kansas City, MO) with the
operating conditions of -50°C and <120 mTorr for 8 hr.

4.2.5

Cell-free Protein Synthesis Reaction
The CFPS reactions were performed in 96 well plate using PANOxSP system for 20 to

180 min at 37 °C[82]. The reactions contained 25 volume percent cell extract, 1.20 nM plasmid
and the following components all from Sigma-Aldrich (St. Louis, MO): 10 to 15 mM magnesium
glutamate, which was optimized based on the extract, 1 mM 1,4-diaminobutane, 1.5 mM
spermidine, 33.33 mM phosphoenolpyruvate (PEP), 10 mM ammonium glutamate, 175 mM
potassium glutamate, 2.7 mM potassium oxalate, 0.33 mM nicotinamide adenine dinucleotide
(NAD), 0.27 mM coenzyme A (CoA), 1.2 mM ATP, 0.86 mM CTP, 0.86 mM GTP, 0.86 mM
UTP, 0.17 mM folinic acid, 2 mM of all the canonical amino acids except glutamic acid. For
experiments requiring the measurement of protein production yield using a scintillation counter,
5 µM l-[U-14C] Leucine (PerkinElmer, Waltham, MA) was added to the reaction, and protein
yield was calculated based on total and washed counts as described previously[83].
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4.2.6

Environmental and Human Samples Tested in Cell-Free Protein Synthesis
Tap water, storm water, and pond water were collected at various locations in Utah

County, USA. Soil and snow samples were collected in Salt Lake County, Utah, where soil
samples were extracted into ddH2O at a one to one (weight to volume) ratio. All of the
wastewater treatment samples were collected from the Provo city water reclamation facility. Raw
sewage was from the influent of the plant. Post clarifier sample was after the primary
sedimentation basins. Post biological sample was the effluent of the aeration basins with
activated sludge. Post filter sample was the activated sludge process effluent (final clarifier
effluent) passed through anthracite filters. The effluent sample was the final product of the plant
after chlorination and dechlorination treatments. The single donor human whole blood-Na
heparin sample was obtained from Innovative Research (Peary Ct, Novi, MI). Urine samples
were obtained from volunteers.

4.2.7

Hormone Biosensor Assay
The Hormone biosensor assay was performed in 2 stages. Stage 1: CFPS of the biosensor

protein in a 96 well plate for 20 min in the presence of 0 to 10 µM TRIAC, T3, or E2 dissolved
in dimethyl sulfoxide (DMSO). For consistency all CFPS reactions were adjusted to have 5
volume percent DMSO. Stage 2: After 20 min, the reactions were diluted 104-fold into PBS
buffer, of which 25 µl was transferred into each well of a UV-transparent Corning® 96 well
plate. The 104-fold CFPS dilution was introduced for optimal signal clarity and to eliminate
overflow readings of our assay instruments, and was used in all experiments. To each well, 175
µl of 228.6 µM nitrocefin in PBS was additionally added to the wells at the same time to achieve
a final nitrocefin concentration of 200 µM. The plates were then directly quantified via plate
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reader (BioTek Synergy Mx) for a nitrocefin-based beta-lactamase activity assay [137].
Specifically, the absorbance was read at 390 and 490 nm wavelengths for unreacted and reacted
substrate nitrocefin, respectively. Measurements were repeated at 1 min intervals, with 10 sec
shaking at each interval to mix, for 15 min. At the end of the assay, the absorbance was read at
760 nm to provide a relative background level for the assay. The rate of nitrocefin conversion
was determined at each ligand concentration using the time course measurements, and the
resulting rates were used to determine the half maximal effective ligand concentration (EC50).

4.2.8

Analysis of Hormone Biosensor Assay Results
The nitrocefin conversion value (NCV) was calculated using Equation 1. The A390 is λmax

of the yellow substrate nitrocefin, while A490 is the λmax of the red nitrocefin conversion product,
and A760 is background absorbance of each well. In order to maximize the signal-to-noise ratio,
the time point with the maximum difference between the NCVs of the negative control (zero
ligand) and maximum ligand concentration was selected to calculate the dose-response curves.
The Four-Parameter Logistic Function (Equation 2) was fitted to this data to yield the half
maximal effective concentration (EC50)[138]. Parameters “a” and “b” define lower and upper
plateau value of the function, respectively, while “k” is the slope factor.
Nitrocefin Conversion Value (NVC)=
Predicted NVC= 𝑎𝑎 +

𝐴𝐴490 −𝐴𝐴760(𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑜𝑜𝑜𝑜 𝑎𝑎𝑎𝑎𝑎𝑎 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤)
𝐴𝐴390 −𝐴𝐴760(𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑜𝑜𝑜𝑜 𝑎𝑎𝑎𝑎𝑎𝑎 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤)
𝑏𝑏−𝑎𝑎

1+(exp�𝑘𝑘(log(𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐)−log(𝐸𝐸𝐸𝐸50 ))�

(4-1)
(4-2)

To generate percentage dose-response graphs, values and predicted values from the fitted

function were normalized based on the equation 3.
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Normalized Dose Response=

(𝑁𝑁𝑁𝑁𝑁𝑁)−𝑀𝑀𝑀𝑀𝑀𝑀(𝑁𝑁𝑁𝑁𝑁𝑁)

𝑀𝑀𝑀𝑀𝑀𝑀(𝑁𝑁𝑁𝑁𝑁𝑁)−𝑀𝑀𝑀𝑀𝑀𝑀(𝑁𝑁𝑁𝑁𝑁𝑁)

∗ 100%

(4-3)

The overall quality of the assays was assessed using Z' factor, signal-to-noise ratio (S/N),
and signal to background ratio (S/B) parameters. The parameters were calculated using a
previously described method[128, 139]. Also, the limit of detection (LOD) was calculated based
on IUPAC methodology by finding the corresponding concentration value for blank
measurement added to its three times standard deviation[140]

Results and Discussion

4.3.1

RAPID Biosensor Design and Rationale
Here we report the RAPID (Rapid Adaptable Portable In-vitro Detection) biosensor for

NHR-binding ligands. The goal of this work was to create a near real-time biosensor platform by
combining our previous cell-based allosterically activated, fusion protein approach[127] with the
open flexibility of CFPS systems[23]. The fusion protein consists of four domains including: 1)
maltose binding domain, which improves the solubility of the fusion protein[125]; 2) mini-intein
domain, which acts as a stabilizing domain for the NHR domain[125]; 3) NHR ligand binding
domain, which is the heart of the biosensor and acts as a switch to activate the reporter enzyme;
and 4) the reporter enzyme. An interaction between a ligand/chemical and the NHR ligand
binding domain causes a conformational change which results in improved reporter protein
activity as previously described[141]. Hence, a signal results from the presence of a
chemical/ligand that binds the NHR ligand binding domain during protein synthesis (Figure
4-1,A, Figure 4-2). Due to the cell-free nature of CFPS, there is no membrane transfer limitation
for chemicals that might target NHRs[2], while the direct translation of the sensor protein
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provides a fast, inexpensive, and convenient assay for the presence of EDC activity in unknown
test chemicals.

Figure 4-1(A) The protein construct for the RAPID biosensor. It includes the Maltose Binding
Protein (MBP) at its N-terminus, a mini-intein splicing domain with an inserted NHR ligand
binding domain (from hTRβ in this work), and a C-terminal reporter enzyme (β-lac in this
work).The presence of ligand during expression of the protein changes the structure of the
biosensor and improves accessibility of the reporter enzyme. (B) CFPS of the biosensor fusion
protein with protein production yields reported for increasing reaction times and in the presence
of three levels of the ligand T3 (total protein = dark bars, soluble protein = light bars, reaction
volume was 20µl). The error bars represent one standard deviation and n=3.
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The initial step in creating the CFPS-based RAPID biosensor was to re-engineer the
reporter protein domain for a rapid and straightforward colorimetric assay readout. Our previous
bacterial biosensor platform employed the thymidylate synthase reporter enzyme to enable
growth phenotype changes[125]. Unfortunately, in vitro assays for thymidylate synthase activity
are cumbersome and require oxygen-sensitive reagents. For these reasons, the β-lactamase (β-lac)
enzyme was selected to replace the thymidylate synthase enzyme due to its similarity in size and
commercially available colorimetric activity assay.
To characterize our RAPID biosensor, the human thyroid receptor β (hTRβ) was chosen
for the initial ligand binding domain due to its robust behavior in our bacterial biosensor[127]. It
also has high sensitivity and selectivity to TRIAC, a potent agonist, with a half-maximal
effective concentration value (EC50) reported at 70 nM. Cloning work to incorporate the β-lac
reporter and hTRβ ligand binding domain into the fusion protein is described in the methods
section, with the final fusion protein sequence illustrated in Figure 4-1,A.

4.3.2

Cell-free Protein Synthesis of the Reporter Fusion Protein
The resulting fusion protein, containing the hTRβ ligand binding domain and β-lac, was

expressed in an E. coli-based CFPS system as detailed in the methods section. To elucidate the
mechanism of activation, total protein titer and protein solubility were measured by tracking the
incorporation of C-14 radiolabeled leucine (Figure 4-1,B). The 92 kD MBP-IN-hTRβ-IC-β-lac
fusion protein was expressed at yields up to 700 µg/mL in 3 hr and the expression level was
unaffected by the presence of T3 ligand. Also, the protein solubility yields were consistently
greater than 85%. The insensitivity of the expressed protein to this ligand, in addition to our
previous work and subsequent experiments shown here, suggest that the expression system and
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biosensor protein solubility are uncoupled from the ligand concentration. Thus, the scaffold is
expressed in a soluble form regardless of ligand, further suggesting a signaling mechanism based
on a structural change in the biosensor protein upon ligand binding, as opposed to a mechanism
based on soluble biosensor expression.

Figure 4-2 Scheme of the RAPID biosensor to detect chemicals that target NHRs. The biosensor
assay includes two steps: 1- CFPS reaction to produce the biosensor, 2- colorimetric assay to
quantify the biosensor protein activation. The presence of ligand during protein synthesis
activates the biosensor by altering the conformation of biosensor enzyme and increasing the
nitrocefin assay signal.
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4.3.3

Hormone Biosensor Assay
The hormone biosensor assay consists of two steps as illustrated in Figure 4-2. First,

cell-free expression of the MBP-IN-hTRβ-IC-β-lac reporter fusion protein is performed in the
presence of the sample to be tested. The resulting protein is then subjected to a colorimetric
reporter enzyme activity assay, where NHR-ligand binding is reflected in the activity of the
reporter enzyme domain (β-lac). The hormone sensing capability of this assay was assessed with
3 known endocrine disrupting chemicals; two chemicals that are known to target hTRβ (TRIAC
and T3), and a negative control (estrogen) that targets the human estrogen receptor NHR but
does not target hTRβ. The results are reported in Figure 4-3, where the EC50, Z' factor, signal-tonoise ratio (S/N), and signal to background ratio (S/B) are calculated for each chemical. The Z'
factor was between 0.5 to 1 for all assays, indicating “an excellent assay” for screening and
sensing[128, 139]. The measured EC50 for TRIAC and T3 were 90 and 607 nM, respectively,
which correspond well to the EC50 from our previous studies with the bacterial biosensor, 70 and
580 nM respectively (Figure 4-3)[127]. Also, the calculated LOD were 48 and 75 nM,
respectively for TRIAC and T3. As expected, a statistically significant signal was not observed
with the estrogen negative control (Figure 4-3,B, square markers, p-value of 0.84). TRIAC was
7-fold more potent than T3 against TRβ which is similar to our bacterial biosensor at 8-fold and
other reported sensors at 6-fold[142]. Although some in vitro binding and transactivation assays
can detect ligands with higher sensitivity, the simplicity, speed, and the lack of toxicity or celluptake complications make the RAPID system a strong candidate for screening of NHR-binding
ligands[142-144].
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Figure 4-3 A) Dose-response curve for the hTRβ biosensor in the presence of TRIAC. B) Doseresponse curves of the hTRβ biosensor in the presence of T3 (triangles), and E2 (squares). C)
The half-maximal effective concentration (EC50), slope factor (k), Z' factor, signal to noise ratio
(S/N), and signal to background ratio (S/B) for the responses against TRIAC, T3, and E2. The
solid lines represent fitted nitrocefin conversion values, the markers represent the average
measured values, and the error bars represent one standard deviation for n=2.

64

One considerable strength of our RAPID biosensor is speed of the assay, with the total
time needed to generate clear results being less than 30 min. Alternatively, mammalian-based
assays may take days to weeks to complete and bacterial-based assays take 24-36 hours[127,
145]. Another strength of the cell-free system is the elimination of confounding issues associated
with membrane transport of test chemicals, unknown or unintended side effects related to cell
growth or toxicity, or cross activation of NHRs[23]. In contrast to other in vitro techniques, a
further advantage of our system is that there is no need for any purification or complex enzyme
stabilization steps[59]. Furthermore, the modular nature of the fusion protein opens the
possibility of optimizing the system by rapidly incorporating new reporter enzymes, while also
expanding the RAPID biosensor to include diverse nuclear hormone receptors for human and
animal applications[146].

4.3.4

Lyophilized Biosensor

To develop our RAPID biosensor platform for potential field use (i.e. outside of the
laboratory), we assessed the possibility of lyophilizing the CFPS biosensor components.
Previously, we reported lyophilized cell extracts remained active after 90 days of storage at room
temperature, and demonstrated the potential for CFPS to be used in biotherapeutic protein
production[147]. For this work, all essential elements, including cell extract, plasmid encoding
the fusion protein, and necessary small molecule additives were combined and lyophilized at the
same time, to create a “just-add-sample” CFPS assay. The results illustrate that lyophilized CFPS
performed similarly to freshly prepared CFPS in detecting TRIAC (85 nM EC50, -5.5 k, 0.81 Z’,
35 S/N, 1.6 S/B, 59 nM LOD) (Figure 4-4). Thus, the RAPID biosensor has the potential to be
used as a field assay for in situ real-time detection of EDCs in essential infrastructure, such as
watersheds.
65

Figure 4-4 Dose-response graph and statistical analysis results for the RAPID biosensor with
lyophilized CFPS components in the presence of TRIAC. The solid line represents fitted
nitrocefin conversion values, while circle markers represent the measured values. Error bars
repre-sent one standard deviation for n=2.

4.3.5

CFPS Performance in Different Environmental Samples
To understand the utility of this new NHR biosensor for evaluating environmental

samples, we tested the performance of the CFPS system – a sensitive component of the RAPID
biosensor – in various untreated water sources, raw sewage, and human bodily fluids (Figure
4-5). For all of the samples, CFPS produced a model protein GFP at sufficient protein production
levels necessary for the biosensor assay. The water samples (tap, pond, snow, storm) and
samples from various stages of a wastewater treatment plant did not significantly affect CFPS
levels, with the exceptions being raw sewage wastewater and post clarifier wastewater. However,
even after adding 47% by volume raw sewage or post clarifier wastewater to CFPS reactions,
greater than 50% of protein production level was maintained. The robustness of CFPS across
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diverse environmental samples indicates the potential for use in diverse environmental
monitoring situations.

Figure 4-5 Protein production capability of CFPS in the presence of environmental and human
samples. In all cases model protein GFP is expressed and the production level (y-axis) is
normalized to GFP production in a standard CFPS with 100 corresponding to 100% of the GFP
production level in standard CFPS. Each sample type is described in the methods section and the
x-axis corresponds to the final concentration for the sample in the CFPS reaction by volume
percent. The error bars represent one standard deviation for n=3.
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Beyond environmental and wastewater samples, we examined CFPS tolerance to human
medical samples, including blood and urine. Greater than 60% of the original CFPS activity was
retained in reactions containing up to 20% by volume human blood. Additionally, we note that
the blood we used in this work contained heparin as anticoagulant in lieu of EDTA, because
EDTA at high concentrations can sequester magnesium and inactivate CFPS[82]. Expectedly,
human urine, which contains a significant concentration (~280 mM) of the protein denaturant
urea[148], had the greatest impact on CFPS activity. However, CFPS activity remained
detectable at up to 8% by volume urine (1% original activity, with a standard deviation of
0.05 %). To account for significant yield changes caused by urine samples, a control CFPS
reaction with a model protein such as GFP could be used in combination with the biosensor to
ensure consistent dilution of the CFPS biosensing protein in the second colorimetric stage of the
biosensor assay. Overall, the ability of CFPS to tolerate high levels of various contaminants,
such as organic matter, bacteria, blood, urine and wastewater demonstrates its robustness as a
biosensing platform.

4.3.6

NHR RAPID Biosensor Performance in an Environmental Sample
Raw sewage was chosen to investigate how the composite biosensor was affected by the

presence of an actual environmental sample. CFPS reactions containing 40% final volume raw
sewage and TRIAC at varying concentrations were reacted for 20 mins. Subsequently, the
reactions were diluted and assayed using the described colorimetric assay, where the responses
are independently normalized to the high and low EDC concentration readings of the assay. The
resulting RAPID biosensor maintained its sensitivity for TRIAC (53 nM EC50, -3.4 k, 0.63 Z’,
40 S/N, 1.7 S/B, 28 nM LOD) (Figure 4-6).
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Figure 4-6 Dose-response graph and statistical analysis results for the RAPID biosensor in the
presence of TRIAC and 40% by volume raw sewage. The solid line represents fitted nitrocefin
conversion values, the circle markers represent the measured values, and the error bars represent
one standard deviation for n=2.

Conclusion
Here we have developed a new RAPID biosensor platform for chemicals that target
nuclear hormone receptors using a quick, versatile cell-free protein synthesis approach. The
developed biosensor has some key advantages over existing biosensors, including near real-time
readout, the potential for portable field use, and reduced labor and cost requirements. This
biosensor is also a promising tool for studying various NHR-binding ligands in a highthroughput manner. Additionally, the ability of CFPS to perform protein synthesis in different
human and environmental samples, showed strong potential of the biosensor for detecting NHRtargeting compounds directly, without requiring purification or modification of the sample.
Overall the RAPID biosensor is an attractive alternative to currently available technology and
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provides a fast, versatile platform for detecting potential NHR-binding ligands including EDCs
and therapeutics.
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5

CONCLUSIONS AND FUTURE WORK

In my presented research, I successfully worked with colleagues and collaborators to lead
the engineering of cell-free protein synthesis technology for 1) sense codon emancipation for
incorporation of multiple unnatural amino acids; 2) expressing a hard-to-express anticancer
biotherapeutic and introducing a just-add-water system; and 3) biosensing ligand that interacts
with nuclear hormone receptors. I have helped advance each field and am excited about the
potential of cell-free systems to revolutionize approaches to these areas. As we move forward, I
have the following thoughts on the direction of future work needed for the advancement of this
research.

Future Work

5.1.1

Codon Emancipation
Our work successfully showed that we can decouple codon-amino acid links by

degrading endogenous tRNA. To emancipate sense codons and eventually incorporating
unnatural amino acids, we need to add back tRNA for a minimal set of tRNAs for the 20
canonical amino acids (one tRNA for each amino acid) and orthogonal tRNA for incorporating
unnatural amino acids from other organisms such as methanocaldococcus jannaschii or
saccharomyces cerevisiae. We used an in vitro transcription method successfully to synthesize
tRNA for both incorporating natural and unnatural amino acids, and this method is expensive
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and labor intensive. For future work, we suggest that instead of making each individual tRNA for
canonical amino acids, we use E. coli bulk-purified tRNAs and then target just the tRNA that
codes for the specific codon selected for emancipation. To do so, we recommend using
complementary single stranded DNA and making a DNA-tRNA hybrid for the selected tRNA,
then using immobilized RNase H to degrade the tRNA. In this way, we can add back the rest of
bulk tRNAs to the system. This method would have a few advantages including: lower cost, and
being a less labor-intensive process, Also, in this approach tRNA comes with all the necessary
post translational modifications. For orthogonal tRNAs, we recommend using the previous
method, involving in vitro transcription.

5.1.2

Expressing a Hard-to-express Anticancer Biotherapeutics
For future work in this area, we suggest combining this technology with linear DNA

template technology and making a large library of mutated genes for onconase. This combined
method has the potential to screen onconcase in a high-throughput manner to find the most
potent gene for producing onconase with the highest level of anticancer activity in a fraction of
time needed for the in vivo approach.

5.1.3

Biosensing Ligand that Interact with Nuclear Hormone Receptors
For this project, we strongly suggest expanding applications of the biosensor by

substituting the nuclear hormone receptor domain to target other known endocrine disrupting
compounds and to screen environmentally released chemicals for potential endocrine disrupting
activity. Also, we recommend using other reporter enzymes for decreasing the cost of enzyme
substrate and improving sensitivity. The modularity of the presented biosensor makes it a
versatile platform for several different biosensing applications.
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